N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS

Abstract: A class of N-arylheteroarylalkyl 1-phenyl-imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of formula (I) wherein A is selected from (a), (b), (c), (d), (e) and (f); wherein m is one; wherein each of R<1>, R<2> and R<3> is independently selected from hybrido, alkyl, alkoxy, cyano, halo, hydroxy, carboxyl, alkoxycarbonyl, formyl and acetyl; alkylcarbonyl and haloalkylcarbonyl; wherein R<4> is hybrido; wherein R<5> is alkyl; wherein R<6> is an acidic group selected from COOH and (g); or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt.

Description: N-ARYLHETEROARYLALKYL l-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS Related Application This is a continuation-in-part of U.S. Application Ser. No. PCT/US92/02439 filed 1 April 1992 which is a continuation-in-part of U.S. Application Ser. No. 07/681,011 filed 5 April 1991. Field of the Invention Non-peptidic N-arylheteroarylalkyl imidazol-2- one compounds are described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Of particular interest are angiotensin II antagonist compounds provided by a 1- phenyl-imidazol-2-one having an arylheteroarylmethyl moiety attached at the 3-nitrogen atom of the 1-phenyl- imidazol-2-one. Background of the Invention The renin-angiotensin system is one of the hormonal mechanisms involved in regulation of pressure/volume homeostasis and in expression of hypertension. Activation of the renin-angiotensin cascade begins with renin secretion from the juxtaglomerular apparatus of the kidney and culminates in the formation of angiotensin II, the primary active species of this system. This octapeptide, angiotensin II, is a potent vasoconstrictor agent and also produces other physiological effects such as promoting aldosterone secretion, promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, increasing vasopressin secretion, causing positive cardiac inotropic effect and modulating other hormonal systems. Previous studies have shown that antagonizing angiotensin II at its receptors is a viable approach to inhibit the renin-angiotensin system, given the pivotal role of this octapeptide which mediates the actions of the renin-angiotensin system through interaction with various tissue receptors. There are several known angiotensin II antagonists, most of which are peptidic in nature. Such peptidic compounds are of limited use due to their lack of oral bioavailability or their short duration of action. Also, commercially-available peptidic angiotensin II antagonists (e.g., Saralasin) have a significant residual agonist activity which further limit their therapeutic application. Non-peptidic compounds with angiotensin II antagonist properties are known. For example, the sodium salt of 2-n-butyl-4-chloro-l- (2- chlorobenzyl)imidazole-5-acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [P. C. Wong et al, J. Pharmacol. Exp. Ther. , 217.(1), 1-7 (1988)]. Also, the sodium salt of 2- butyl-4-chloro-l- (2-nitrobenzyl)imidazole-5-acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [A. T. Chiu et al, European J. Pharmacol., lϋZ, 13-21 (1988)]. A family of l-benzylimidazole-5-acetate derivatives has been shown to have competitive angiotensin II antagonist properties [A. T. Chiu et al, J. Pharmacol. Exp. Ther.. 25H (3 ) , 867-874 (1989)]. U.S. Patent No. 4,816,463 to Blankey et al describes a family of 4,5,6,7-tetrahydro-lH- imidazo (4, 5-c) -tetrahydro-pyridine derivatives useful as antihypertensives, some of which are reported to antagonize the binding of labelled angiotensin II to rat adrenal receptor preparation and thus cause a significant decrease in mean arterial blood pressure in conscious hypertensive rats. EP No. 253,310, published 20 January 1988, describes a series of aralkyl imidazole compounds, including in particular a family of biphenylmethyl substituted i idazoles, as antagonists to the angiotensin II receptor. EP No. 323,841 published 12 July 1989 describes four classes of angiotensin II antagonists, namely, biphenylmethylpyrroles, biphenylmethylpyrazoles, biphenylme hyl-1,2,3-=triazoles and biphenylmethyl 4-substituted-4H-l,2, -triazoles, including the compound 3,5-dibutyl-4-[ (2 ' - carboxybiphenyl-4-yl)methyl] -4H-1,2,4-triazole. U.S. Patent No. 4,880,804 to Carini et al describes a family of biphenylmethylbenzimidazole compounds as angiotensin II receptor blockers for use in treatment of hypertension and congestive heart failure. There are several families of known compounds having one or two oxo substituents on a triazole ring. For example, East German Patent No. 160,447 published 3 August 1983 describes a family of 1,2, 4-triazolin-5-one compounds, specifically 2, 4-dihydro-4, 5- bis (phenylmethyl) -3H-1,2,4-triazol-3-one, for use as herbicides. Belgian Patent No. 806,146 published 16 October 1972 describes a family of triazolinone compounds, including the cpmpound (3- (4-m-chlorophenyl- 1-piperazinyl) -propyl) -3, 4-diethyl-l,2, 4-triazolin-5- one, having tranquilizer, hypotensive and analgesic activities. Belgian Patent No. 631,842 published 28 February 1963 describes a family of 1, 2, 4-triazolones having hypnotic, tranquilizer, narcotic, sedative and analgetic activities, which includes a class of 4-N- aralkyl-l,2,4-triazol-5-one compounds. EP #7,180 published 15 June 1978 describes a family of 1,2- disubstituted-4-alkyl-l,2, -triazolidine-3,5-dione compounds having a wide variety of activities, such as antiulcer, bronchodilator, antifertility and cardiovascular-related activities which include an ihypertensive, antiarrhythmic, platelet aggregation inhibition and smooth muscle activities. EP #283,310 published 18 March 1987 describes a family of N 1 - diarylmethyl-N 2 -aminoalkyl-diaza-heterocyclic derivatives for treating cerebral vascular and ischemic diseases and for protecting against anoxia. DESCRIPTION OF THE INVENTION A class of N-substituted arylheteroarylalkyl l-phenyl-imidazol-2-one compounds useful in treating circulatory disorders, particularly cardiovascular disorders, is defined by Formula I: wherein A is selected from wherein m is a number selected from one to four, inclusive; wherein each of R 1 , R 2 and R3 is independently selected from hydrido, alkyl, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and haloalkylcarbonyl; wherein R 4 is selected from hydrido, alkyl, halo, haloalkyl, formyl, carboxyl and alkoxyalkyl; wherein R 5 is selected from alkyl, phenyl, phenylalkyl, cycloalkyl and cycloalkylalkyl; wherein R--> is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Regioisomers of compounds of Formula I are also embraced as part of the invention, particularly those regioisomers formed by various substitutions on nitrogen atoms of the imidazole ring relative to substitutions on the carbon atoms of the imidazode ring. For purposes of nomenclature, a numbering system for the imidazole ring is shown below for a preferred set of compounds of the invention within Formula I: Compounds of Formula I would be useful in treating a variety of circulatory disorders and circulatory-related disorders, including cardiovascular disorders, such as hypertension, congestive heart failure and arteriosclerosis, and to treat other disorders such as glaucoma. These compounds would also be useful as adjunctive therapies. For example, compounds of Formula I may be used in combination with other drugs, such as a diuretic, to treat hypertension. Also, compounds of Formula I could be used in conjunction with certain surgical procedures. For example, these compounds could be used to prevent post-angioplasty re-stenosis. Compounds of Formula I are therapeutically effective in treatment of cardiovascular disorders by acting as antagonists to, or blockers of, the angiotensin II (All) receptor. Compounds of Formula I would be therapeutically effective in treatment of the above-mentioned circulatory and cardiovascular disorders or would be precursors to, or prodrugs of, therapeutically-effective compounds. Within Formula I there is a first group of compounds of more interest as represented by Formula II: wherein each of R 1 , R 2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert- butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R^ is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentyl ethyl, cyclopentyle hyl, cyclohexylmethyl and cyclohexylethyl; wherein R*-> is an acidic group selected from COOH and H I or a εtereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Within this first group of compounds of Formula II there is a first class of higher-interest compounds wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R^ is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this first class of higher-interest compounds of the first group of compounds of Formula II consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2-methylphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (1H- tetrazol-5-yl)pheny1] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-propylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl] ethyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl) -4-propyl-l,3-dihydro-3-[ [5-[2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl] ethyl] -2H-imidazol-2- one; 1- (2-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-bromophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-iodophenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-hydroxyphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1-(2-cyanophenyl)-4-propyl-l,3-dihydro-3-[ [5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one; 1-(2-carboxyphenyl)-4-propyl-l,3-dihydro-3-[ [5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H-imidazol-2* one; 1-(2-aminophenyl)-4-propyl-l,3-dihydro-3-[ [5-[2-(1H- tetrazol-5-yl) henyl]-2-pyridinyl]methyl] -2H-imidazol-2- one; l-(2-acetylphenyl)-4-propyl-l,3-dihydro-3-[ [5-[2-(lH- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-trifluoroacetylphenyl)-4-propyl-l,3-dihydro-3-[[5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-methylphenyl)-4-butyl-l,3-dihydro-3-[ [5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one; l-(2-ethylphenyl)-4-butyl-l,3-dihydro-3-[ [5-[2-(lH- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-propylpheny1)-4-butyl-1,3-dihydro-3- [ [5-[2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl) -4-butyl-l,3-dihydro-3-[ [5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-tertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [5-[2-(1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H-imidazol-2- one; 1-(2-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [5-[2- (1H- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; l-(2-bromophenyl) -4-butyl-l, 3-dihydro-3-[ [5-[2-(lH- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-iodophenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; l-(2-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [5-[2-(lH- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-hydroxyphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; l-(2-cyanophenyl) -4-butyl-l, 3-dihydro-3-t [5- [2- (1H- tetrazol-5-yl) henyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-carboxyphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-aminophenyl) -4-butyl-l, 3-dihydro-3-[ [5-[2-(lH- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-acetylphenyl) -4-butyl-l,3-dihydro-3- [ [5-[2-(lH- tetrazol-5-yl) henyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; and 1- (2-trifluoroacetylphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one. Within this first group of compounds of Formula II there is a second class of higher-interest compounds wherein each of R 1 and R2 is independently selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R 3 and R4 is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this second class of higher-interest compounds of the first group of compounds of Formula II consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2, 6-dimethylphenyl) -4-propyl-l,3-dihydro-3-[ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-ethylphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (IH- etrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-orie; 1- (2-methyl-6-isopropylphenyl)-4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl] ethyl]-2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methylphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-diethylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropylphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-tertbutylphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-6-isopropylphenyl)-4-propyl-l,3-dihydro-3- [[5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [5- [2-(IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-6-methoxyphenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methylphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-ethylphenyl)-4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2,6-diisopropylphenyl)-4-propyl-l,3-dihydro-3-[[5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutylphenyl)-4-propyl-l,3-dihydro- 3-[ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3- t [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropylphenyl) -4-propyl-l,3-dihydro- 3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- 2H-imidazol-2-one; l-(2,6-ditertbutylphenyl)-4-propyl-l,3-dihydro-3-[[5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethylphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2,6-difluorophenyl) -4-propyl-l,3-dihydro-3-[ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-fluoro-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-methylphenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-ethylphenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-isopropylphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2,6-dichlorophenyl) -4-propyl-l,3-dihydro-3-[ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-isopropylphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-tertbutyIphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (IH- etrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [.[5- [2- ( lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-isopropylphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-propyl-l, 3-dihydro-3- [ [5- [2- (IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2,6-dimethoxyphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl)-4-propyl-l,3-dihydro'-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-tertbutyIphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl)-4-propyl-l,3-dihydro-3- [ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-methyIphenyl)-4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dimethyIphenyl) -4-butyl-l,3-dihydro-3-[ [5-[2-(lH- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-methyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [5-[2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2-methyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[[5- [2-(IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [5-[2- (IH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2,6-diethyIphenyl) -4-butyl-l,3-dihydro-3-[ [5-[2-(lH- tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H-imidazol-2- one; 1- (2-ethyl-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2-ethyl-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [5-[2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; l-(2-ethyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl) henyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [5-[2* (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-isopropylphenyl) -4-butyl-l, 3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-tertbutyIphenyl)-4-butyl-l, 3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2-(lH-tetrazol-5-yl)ρhenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-ethylphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-diisopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [5-[2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [5- [ 2 - (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2-isopropyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl)-4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-tertbutyl-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2,6-ditertbutyIphenyl)-4-butyl-l,3-dihydro-3-[ [5-[2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl)-4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl]-2H- imidazol-2-one; l-(2-tertbutyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-me hoxyphenyl)-4-butyl-1,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (IH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2-fluoro-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [5-[2- (IH-tetrazol-5-yl)phenyl]-2-pyridinyl]me hyl]-2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-difluorophenyl) -4-butyl-l,3-dihydro-3- [ [5-[2-(lH- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-fluoro-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; l-(2-chloro-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (IH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dichlorophenyl) -4-butyl-l,3-dihydro-3-[ [5-[2- (1H- tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-chloro-6-methoxyphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [5-[2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-tertbutylphenyl)-4-butyl-l,3-dihydro-3- [ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [5- [2-(lH-tetrazol-5-yl)phenyl]-2-ρyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl] ethyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- t [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-one; l-(2-acetyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-t [5- [2- (lH-tetrazol-5-yl) henyl] -2-pyridinyl]methyl] -2H- imidazol-2-one; and 1- (2-acetyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [5- [2- (lH-tetrazol-5-yl)phenyl] -2-pyridinyl]methyl] -2H- imidazol-2-one. Within Formula I there is a first group of compounds of more interest as represented by Formula III: wherein each of R 1 , R 2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R 4 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoro ethyl, trifluoro ethyl, formyl, carboxyl and dimethoxymethyl; wherein 5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Within this first group of compounds of Formula III there is a first class of higher-interest compounds each of Rl is selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, ' chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R^ is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoαsomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 9. A family of specific compounds of particular interest within this first class of higher-interest compounds of the first group of compounds of Formula III consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2-methyIphenyl)-4-propyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1-(2-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1-(2-propyIphenyl)-4-propyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1-(2-isopropylphenyl)-4-propyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1-(2-tertbutylphenyl)-4-propyl-l,3-dihydro-3-[ [6- [2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl] ethyl] -2H-imidazol-2- one; 1- (2-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H-imidazol-2- one; 1- (2-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-bromophenyl) -4-propyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-iodophenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2* one ; 1- (2-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H-imidazol-2* one; 1- (2-hydroxyphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; l-(2-cyanophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-carboxyphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-aminophenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-acetyIphenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-trifluoroacetyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-ethyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-propyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2* one; 1- (2-tertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one; l-(2-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2- one; l-(2-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl] ethyl] -2H-imidazol-2- one; 1-(2-bro ophenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1-(2-iodophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; l-(2-hydroxyphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-cyanophenyl)-4-butyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-carboxyphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-aminophenyl)-4-butyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-acetyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl) henyl] -3-pyridinyl]me hyl] -2H-imidazol-2- one; and 1- (2-trifluoroacetyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one. 10. Within this first group of compounds of Formula III there is a second class of higher-interest compounds wherein each of R _ and R2 is independently selected from methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R 3 and R4 is hydrido; wherein RR is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R 6 is an acidic group selected from COOH; and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 11. A family of specific compounds of particular interest within this second class of higher-interest compounds of the first group of compounds of Formula III consists of compounds and their stereoisomers and tauto ers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2, 6-dimethyIphenyl) -4-propyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-ethylphenyl)-4-propyl-l,3-dihydro-3-[ [6- [2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-methyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-tertbutyIphenyl)-4-propyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [6- [2-(IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[[6- [2- (lH-tetrazol-5-yl) henyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-methyIphenyl)-4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2,6-diethylphenyl)-4-propyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropylphenyl) -4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-ρyridinyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (IH- etrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2-(lH-tetrazol-5-yl)ρhenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-isopropylphenyl)-4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propy1-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methyIphenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-ethylphenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2,6-diisopropyIphenyl)-4-propyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-isopropyl-6-tertbutyIphenyl)-4-propyl-l,3-dihydro- 3-[ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] - 2H-imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-isopropyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl)-4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl)-4-propyl-l,3-dihydro-3- [ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-tertbutyl-6-ethylphenyl)-4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro- 3-t [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]- 2H-imidazol-2-one; 1- (2,6-ditertbutyIphenyl)-4-propyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropylphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- t [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-difluorophenyl) -4-propyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-chlorophenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl) henyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dichlorophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; l-(2-bromo-6-ethylphenyl)-4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-isopropylphenyl) -4-propyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-tertbutylphenyl) -4-propyl-l, 3-dihydro-3- [ [6-[2- ( lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-propyl-l,3-dihydro-3- t [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-propyl-l,3-dihydro-3- t [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl) -4-propyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-propyl-l, 3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2-(IH- etrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl)-4-propyl-l,3-dihydro-3- t [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-methylphenyl)-4-propyl-l,3-dihydro-3-[ [6- [2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro-3- [ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl)-4-propyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dimethyIphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-methyl-6-ethylphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methy1-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; l-(2-methyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-diethylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-tertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; l-(2-ethyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [6- [2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methylphenyl)-4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-6-ethylphenyl)-4-butyl-l,3-dihydro-3-[[6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-tertbutylphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl] ethyl]-2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [6- [2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methylphenyl)-4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2, 6-diisopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (IH- etrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-ethylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-ditertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)ρhenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2-tertbutyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[[6- [2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-fluoro-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-fluoro-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-fluoro-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2,6-difluorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl) henyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-fluoro-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyi]-2H- imidazol-2-one; 1- (2-chloro-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; l-(2-chloro-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dichlorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one; 1- (2-chloro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2-(IH-tetrazol-5-yl) henyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-methoxy-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[[6- [2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1-(2-methoxy-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [6- [2- (IH-tetrazol-5-yl)phenylJ-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2,6-dimethoxyphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one; 1- ( 2-carboxy-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]me hyl]-2H- imidazol-2-one; 1- (2-carboxy-6-tertbutylphenyl)-4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- {lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one; and 1- (2-acetyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one. Within Formula I there is a first group of compounds of more interest as represented by Formula IV: wherein each of R^, R 2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert- butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R^ is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R 6 is an acidic group selected from COOH and H I or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Within this first group of compounds of Formula IV there is a first class of higher-interest compounds wherein each of R^ is selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R 4 is hydrido; wherein R^ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this first class of higher-interest compounds of the first group of compounds of Formula IV consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of1- (2-methylphenyl) - 4-propyl-l, 3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2- pyridinyl]phenyl]methyl] -2H-imidazol-2-one; 1- (2-ethyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-propyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-tertbutylphenyl) -4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(lH- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-bromophenyl)-4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-iodophenyl) -4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (1H- tetrazol-5-yl)-2-pyridinylIphenyl]methyl] -2H-imidazol-2- one; 1- (2-hydroxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl] henyl]methyl] -2H-imidazol-2- one; 1- (2-cyanophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-carboxyphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-aminophenyl) -4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl) -2-pyridinyl]phenyl]me hyl] -2H-imidazol-2- one; 1- (2-acetyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-trifluoroacetyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methylphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethyIphenyl)-4-butyl-1,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-propyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl] ethyl] -2H-imidazol-2- one; 1-(2-isopropylphenyl)-4-butyl-1,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-tertbutylphenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-fluorophenyl)-4-butyl-l,3-dihydro-3- [ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl] ethyl] -2H-imidazol-2- one; 1-(2-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-bromophenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl] ethyl] -2H-imidazol-2- one; 1- (2-iodophenyl) -4-butyl-l,3-dihydro-3-[ [4-[3-(lH- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-hydroxyphenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-cyanophenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -2-pyridinyl] henyl]methyl] -2H-imidazol-2- one; 1-(2-carboxyphenyl) -4-butyl-1,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; l-(2-aminophenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-acetylphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; and 1- (2-trifluoroacetyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl) -2-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one. Within this first group of compounds of Formula IV there is a second class of higher-interest compounds wherein each of R 1 and R2 is independently selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this second class of higher-interest compounds of the first group of compounds of Formula IV consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2, 6-dimethyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-tertbutyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1-(2,6-diethyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[3-(lH- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-ethyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl) -2-pyridinyl] henyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-fluorophenyl)-4-propyl-1,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-ethyl-6-methoxyphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4— [3- (IH-tetrazol-5-y1) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methylphenyl) -4-propyl-1,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-ethyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2 , 6-diisopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro- 3-[ [4-[3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-ethyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-tertbutyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro- 3-[ [4-[3- (IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]- 2H-imidazol-2-one; 1- (2,6-ditertbutylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-tertbutyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-tertbutyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-tertbutyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-fluoro-6-methyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl] henyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropylphenyl)-4-propyl-l,3-dihydro-3- [ [4- 13- (IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2, 6-difluorophenyl) -4-propyl-l,3-dihydro-3-[ [4-[3- (IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-fluoro-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3 - ( lH-tetrazol-5-yl ) -2-pyridinyl] phenyl] methyl ] -2H- imidazol-2-one; 1- (2, 6-dichlorophenyl) -4-propyl-l, 3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-2-pyridinyl] henyl] ethyl]-2H- imidazol-2-one; 1-(2-bromo-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-ethylphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl)-4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2, 6-dimethoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one,-- 1- (2-carboxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl] henyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-y1) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethylphenyl) -4-propyl-1,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-acetyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-acetyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2,6-dimethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-methyl-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methy1-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2,6-diethylphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-tertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; l-(2-ethyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-isopropyIphenyl)-4-butyl-l, 3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-butyl-l , 3-dihydro-3- [ [4- [ 3 - ( IH- tetrazol-5 -yl ) -2-pyridinyl ] phenyl ] methyl ] -2H- imidazol-2-one; 1- (2 -propyl- 6 -methoxyphenyl ) -4-butyl-l , 3 -dihydro-3 - [ [ 4- [3 - (lH-tetrazol-5-yl) -2-pyridinyl]phenyl] methyl ] -2H- imidazol - 2 -one ; 1- (2-isopropyl-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-isopropyl-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2,6-diisopropyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl)-2-pyridinylIphenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[3-(IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-isopropyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-ditertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methy1] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- C [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-difluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-fluoro-6-chlorophenyl) -4-butyl-l, 3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-fluoro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-chloro-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2,6-dichlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (1H- tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-chloro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-y1) -2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-ethylphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-bromo-6-isopropylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-bromo-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-ethyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-β-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazo1-2-one; 1- (2-methoxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-carboxy-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4- [3-(IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(IH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-acetyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-2-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; and 1- (2-acetyl-6-methoxyphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -2-pyridinyl]phenyl]methyl] -2H- imidazol-2-one. Within Formula I there is a first group of compounds of more interest as represented by Formula V: wherein each of R1, R 2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R 4 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dime hoxymethy1; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R6 is an acidic group selected from COOH and H I or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Within this first group of compounds of Formula v there is a first class of higher-interest compounds wherein each of Έ - is selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R 4 is hydrido; wherein R 5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R 5 is an acidic group selected from COOH and H I or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this first class of higher-interest compounds of the first group of compounds of Formula v consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1-(2-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[4-(lH- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-propyIphenyl)-4-propyl-l,3-dihydro-3-[ [4-[4-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl) -4-propyl-l,3-dihydro-3-[ [4-[4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-tertbutylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[4-(1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4-[4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; 1- (2-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4-[4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-bromophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-iodophenyl) -4-propyl-l,3-dihydro-3-[ [4-[4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-hydroxyphenyl)-4-propyl-l,3-dihydro-3-[ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- ( 2 -cyanophenyl ) -4-propyl-l , 3 -dihydro -3 - [ [ 4- [ 4 - ( 1H- tetrazol-5 -yl ) -3 -pyricAnyl ] phenyl ] methyl ] -2H-imidazol-2 - one ; 1- (2-carboxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-aminophenyl) -4-propyl-l,3-dihydro-3- [ [4-[4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-acetylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[4-(lH- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-trifluoroacetylphenyl)-4-propyl-l,3-dihydro-3-[ [4- [4- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4-[4-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H-imidazol-2- one; 1- (2-propyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl) -4-butyl-l,3-dihydro-3-[ [4-[4- (1H- tetrazol-5-yl) -3-pyridinyl] henyl]methyl] -2H-imidazol-2- one; 1-(2-tertbutylphenyl) -4-butyl-l,3-dihydro-3-[ [4-[4- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [4-[4-(1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H-imidazol-2- one; 1- (2-bromophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-iodophenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4-[4-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-hydroxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-cyanophenyl) -4-butyl-l, 3-dihydro-3-[ [4- [4- (1H- tetrazol-5-y1) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-carboxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-aminophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-acetyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; and 1- (2-trifluoroacetyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one. Within this first group of compounds of Formula V there is a second class of higher-interest compounds wherein each of R 1 and R2 is independently selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R 3 and R4 is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this second class of higher-interest compounds of the first group of compounds of Formula V consists of compounds and; their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2,6-dimethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methy1-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-chlorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-diethyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[4-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazoi-2- one; 1- (2-ethyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro-3- [ [4-[4-(IH-tetrazol-5-yl)-3-pyridinyl] henyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-β-tertbutylphenyl)-4-propy1-1,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-propyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-isopropyl-6-methyIphenyl)-4-propyl-l,3-dihydro-3- [ [4- [4-(IH-tetrazol-5-yl)-3-pyridinyl]phenyl] ethyl]-2H- imidazol-2-one,- 1- (2-isopropyl-6-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2, 6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[4- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro- 3-[ [4-[4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3- [ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro- 3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] - 2H-imidazol-2-one; 1- (2 , 6-ditertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2,6-difluorophenyl)-4-propyl-l,3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]me hyl]-2H- imidazol-2-one; 1-(2-fluoro-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methyIphenyl)-4-propyl-l,3-dihydro-3-[[4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-chloro-6-ethyIphenyl)-4-propyl-l,3-dihydro-3 - [ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutyIphenyl)-4-propyl-l,3-dihydro-3- [ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2, 6-dichlorophenyl) -4-propyl-l,3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-chloro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-isopropylphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-tertbutylphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methoxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [4-(IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2,6-dimethoxyphenyl)-4-propyl-l,3-dihydro-3-[ [4-[4- (1H-tetrazol-5-yl)-3-pyridinylIphenyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-methyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]ρhenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridiny1]pheny1]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-propyl-1,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [4-(lH-tetrazol-5-yD -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2,6-dimethylphenyl) -4-butyl-l,3-dihydro-3- [ [4-[4-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-methyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-methyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-methyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2,6-diethyIphenyl)-4-butyl-l,3-dihydro-3-[[4-[4- (1H- tetrazol-5-y1)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-ethyl-6-isopropylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [4- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-ethyl-6-tertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; l-(2-ethyl-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; l-(2-ethyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [4- [4- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl] henyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (IH-tetrazol-5-y1) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- t [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methylphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-isopropyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-tertbutyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2,6-ditertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl)-4-butyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl)-3-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3- [ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-difluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-fluoro-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-ethylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-chloro-6-fluorophenyl) -4-butyl-l, 3-dihydro-3-[ [4- [4- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dichlorophenyl) -4-butyl-l,3-dihydro-3- [ [4-[4-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H-imidazol-2- one; 1- (2-chloro-6-methoxyphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-bromo-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-bromo-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[4- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-bromo-6-isopropylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-bromo-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [4-[4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]me hyl]-2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[4- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4-[4- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4-(lH-tetrazol-5-yD -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [4- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-acetyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-acetyl-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[4- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-acetyl-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3- [ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [4-(IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-acetyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; and 1- (2-acetyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [4- [4-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one. Within Formula I there is a first group of compounds of more interest as represented by Formula VI: wherein each of R 1 , R 2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methy1amino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R^ is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R6 is an acidic group selected from COOH and H I or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Within this first group of compounds of Formula vi there is a first class of higher-interest compounds wherein each of R 1 is selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R^ is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this first class of higher-interest compounds of the first group of compounds of Formula VI consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-ethylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-propyIphenyl) -4-propyl-1,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-y1)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-tertbutylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; 1-(2-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-4-pyridinyl-]phenyl]methyl] -2H-imidazol-2- one; 1- (2-bromophenyl)-4-propyl-l,3-dihydro-3- [ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]me hyl] -2H-imidazol-2- one; l-(2-iodophenyl) -4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-methoxyphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(lH- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-hydroxyphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; l-(2-cyanophenyl) -4-propyl-l,3-dihydro-3- [ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-carboxyphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-aminophenyl) -4-propyl-l,3-dihydro-3- [ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-acetyIphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-trifluoroacetyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-ethyIphenyl) -4-butyl-1,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-propyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-isoproρylphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-4-pyrid„ayl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-tertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-fluorophenyl)-4-butyl-l,3-dihydro-3- [ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; l-(2-bromophenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; 1-(2-iodophenyl) -4-butyl-l,3-dihydro-3-[ [4-[3-(lH- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-hydroxyphenyl) -4-butyl-l,3-dihydro-3-[ [4-[3-(1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-cyanophenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-carboxyphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-a inophenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-acetyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[3- (1H- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; and 1- (2-trifluoroacetyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one. Within this first group of compounds of Formula VI there is a second class of higher-interest compounds wherein each of R 1 and R2 is independently selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R 3 and R4 is hydrido; wherein R•- is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H I or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this second class of higher-interest compounds of the first group of compounds of Formula VI consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1-(2,6-dimethyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(IH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl] ethyl]-2H- imidazol-2-one; 1- (2-methyl-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinylIphenyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-methylphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2, 6-diethylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3-(lH- tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; l-(2-ethyl-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-ethyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-chlorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- t [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methylphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl] henyl]methyl] -2H- imidazol-2-one; 1- (2-propy1-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-ethyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2,6-diisopropyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-isopropyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro- 3-[ [4-[3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl)-4-propyl-1,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl)- -pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-isopropyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl)-4-propyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-tertbutyl-6-methylphenyl)-4-propy1-1,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-ethylphenyl)-4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro- 3-[ [4-[3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] - 2H-imidazol-2-one; 1- (2,6-ditertbutylphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl) -4-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1-(2-tertbutyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-tertbutyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-difluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-dH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]me hyl] -2H- imidazol-2-one; 1-(2-chloro-6-tertbutyIphenyl)-4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2,6-dichlorophenyl) -4-propyl-1,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-f [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-methylphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-bromo-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-isopropyIphenyl)-4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-bromo-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-bromo-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-ρyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-bromo-6-methoxyphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- ( lH-tetrazol-5-yl) -4-ρyridinyl]phenyl] methyl ] -2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]me hyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3 - dH-tetrazol-5-yl ) -4-pyridinyl] phenyl] methyl ] -2H- imidazol-2-one; 1- (2-carboxy-6-ethylphenyl ) -4-propyl-l , 3-dihydro-3 - [ [ 4- [3- ( IH- tetrazol- 5-yl ) -4 -pyridinyl ] phenyl] methyl] -2H- imidazol- 2 -one ; 1- (2-carboxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-carboxy-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-y1)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-carboxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl)-4-propyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-methylphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-acetyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2,6-dimethyIphenyl) -4-butyl-1,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]me hyl] -2H-imidazol-2- one; 1- (2-methy1-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methy1-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinylIphenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-y1) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-methyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2 , 6-diethylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-y1) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4-[3* (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-ethyl-6-chloroρhenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-ethyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propy1-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-isopropylphenyl)-4-butyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-propy1-6- ertbutyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-propyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methy1]-2H- imidazol-2-one; 1-(2-isopropyl-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-ethylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2,6-diisopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2, 6-ditertbutyIphenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-tertbutyl-6-methoxyphenyl)-4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2, 6-difluorophenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]me hyl] -2H-imidazol-2- one; 1- (2-fluoro-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]me hyl] -2H- imidazol-2-one; 1- (2-chloro-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl] henyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]me hyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dichlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (1H- tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-chloro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-bromo-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-butyl-1,3-dihydro-3-[ [4-[3* (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (IH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(IH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methoxy-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methoxy-6-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [3-(IH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4-[3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazo1-2-one; 1-(2-carboxy-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-carboxy-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl)-4-pyridinyl]phenyl]me hyl]-2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl)-4-pyridinyl]phenyl]me hyl] -2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [3-(lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (lH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; and 1- (2-acetyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [3- (IH-tetrazol-5-yl) -4-pyridinyl]phenyl]methyl] -2H- imidazol-2-one. Within Formula I there is a first group of compounds of more interest as represented by Formula vii: wherein each of R^, R 2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert- butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethyla ino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R^ is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R 5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Within this first group of compounds of Formula VII there is a first class of higher-interest compounds wherein each of R! is selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R 4 is hydrido; wherein R^ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this first class of higher-interest compounds of the first group of compounds of Formula VII consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethylphenyl) -4-propyl-l,3-dihydro-3- [ [4-[2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-propyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-isopropyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-tertbutylphenyl) -4-propyl-l,3-dihydro-3-[ [4-[2-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H-imidazol-2- one; 1- (2-bro ophenyl) -4-propyl-l,3-dihydro-3- [ [4-[2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-iodophenyl)-4-propyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-hydroxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-cyanophenyl) -4-propyl-l,3-dihydro-3- [ [4-[2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-carboxyphenyl) -4-propyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-aminopheny1)-4-propyl-1,3-dihydro-3-[ [4-[2-(1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-acetyIphenyl) -4-propyl-l,3-dihydro-3-[ [4-[2-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]me hyl] -2H-imidazol-2- one; 1- (2-trifluoroacetyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-{2-ethyIphenyl) -4-butyl-1,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-propyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-tertbutylphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-bromophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-iodophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H-imidazol-2- one; 1- (2-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; l-(2-hydroxyphenyl)-4-butyl-l,3-dihydro-3-[ [4-[2-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-cyanophenyl) -4-butyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1-(2-carboxyphenyl)-4-butyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazoi-2- one; l-(2-aminophenyl) -4-butyl-l,3-dihydro-3-[ [4-[2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-acetyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[2-(1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; and 1- (2-trifluoroacetyIphenyl)-4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one. Within this first group of compounds of Formula VII there is a second class of higher-interest compounds wherein each of R 1 and R2 is independently selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A family of specific compounds of particular interest within this second class of higher-interest compounds of the first group of compounds of Formula VII consists of compounds and their stereoisomers and tautomers and the pharmaceutically-acceptable salts thereof, said compounds consisting of 1- (2, 6-dimethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imιdazol-2-one; 1- (2-methyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methylphenyl)-4-propyl-l,3-dihydro-3-[ [4- [2- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2,6-diethylphenyl) -4-propyl-l,3-dihydro-3-[ [4-[2-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[2-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propy1-6-ethyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-propy1-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-propy1-6-tertbutyIphenyl) -4-propyl-1,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-ethylphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-diisopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutylphenyl) -4-propyl-l,3-dihydro- 3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] - 2H-imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [[4-[2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2 -tertbutyl-6 -ethy Iphenyl ) -4-propyl-l , 3 -dihydro-3 - [ [ 4 - [2 - (lH-tetrazol-5-yl ) -3 -pyridinyl I phenyl] methyl ] -2H- imidazol-2 -one ; 1- (2-tertbutyl-6-isopropyIphenyl)-4-propyl-l,3-dihydro- 3-[ [4-[2-(IH-tetrazol-5-y1) -3-pyridinyl]phenyl]methyl] - 2H-imidazol-2-one; 1- (2,6-ditertbutyIphenyl)-4-propyl-l,3-dihydro-3-[ [4-[2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3- [ [4-[2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3- [ [4- [2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl)-4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[2- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2, 6-difluorophenyl) -4-propyl-l,3-dihydro-3- [ [4-[2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-chlorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (IH-tetrazol-5-y1) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-tertbutylphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2, 6-dichlorophenyl) -4-propyl-l,3-dihydro-3- [ [4-[2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-bromo-6-ethylphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-bromo-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4-[2-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-tertbutylphenyl)-4-propyl-l,3-dihydro-3- [ [4-[2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-bromo-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [2-(IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methoxyphenyl)-4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-methylphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-methoxy-6-ethyIphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-methylphenyl) -4-propyl-l, 3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl) -4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-propyl-l, 3-dihydro-3- [ C4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-acetyl-6-tertbutyIphenyl)-4-propyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-acetyl-6-fluorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-acetyl-6-chlorophenyl)-4-propyl-l,3-dihydro-3-[ [4- [2-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-acetyl-6-methoxyphenyl) -4-propyl-l,3-dihydro-3-[ [4- [2-(IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2,6-dimethyIphenyl) -4-butyl-l,3-dihydro-3-[ [4-[2-(lH- tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-methyl-6-ethyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [4-[2-(lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-methyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [ 2 - (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2 , 6-diethylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-ethyl-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-ethyl-6-tertbutyIphenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-ethyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-ethyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propy1-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-tertbutylphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propyl-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-propy1-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-ethylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [2-(IH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2,6-diisopropyIphenyl)-4-butyl-l,3-dihydro-3-[ [4-[2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-isopropyl-6-chlorophenyl)-4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-isopropyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methyIphenyl)-4-butyl-l,3-dihydro-3- [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- ιmidazol-2-one; 1- (2-tertbutyl-6-ethylphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-ditertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]me hyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-tertbutyl-6-methoxyphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-ethyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- i idazol-2-one; 1- (2-fluoro-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl] ethyl] -2H- imidazol-2-one; 1- (2 , 6-difluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (1H- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-fluoro-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [2-(IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-fluoro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-methylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [ 2 - (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-chloro-6-ethylphenyl)-4-butyl-1,3-dihydro-3-[ [4-[2- (1H-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-isopropyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[2-(lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-chloro-6-tertbutyIphenyl)-4-butyl-l,3-dihydro-3- [ [4-[2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-chloro-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]me hyl] -2H- imidazol-2-one; 1- (2, 6-dichlorophenyl) -4-butyl-l,3-dihydro-3-[ [4-[2-(lH- tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H-imidazol-2- one; 1- (2-chloro-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-methylphenyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-ethylphenyl)-4-butyl-1,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-bromo-6-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-bromo-6-tertbutylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-fluorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-bromo-6-chlorophenyl)-4-butyl-l,3-dihydro-3-[ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1-(2-bromo-6-methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-methylphenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl)-3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-ethylphenyl)-4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4-[2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1-(2-methoxy-6-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl]-2H- imidazol-2-one; 1- (2-methoxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-methoxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2, 6-dimethoxyphenyl) -4-butyl-l,3-dihydro-3-[ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-ethylphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-isopropyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-fluorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-carboxy-6-methoxyphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; l-(2-acetyl-6-methyIphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-ethyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-isopropyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-tertbutyIphenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazo..L-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-fluorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (IH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; 1- (2-acetyl-6-chlorophenyl) -4-butyl-l, 3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one; and 1- (2-acetyl-6-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [4- [2- (lH-tetrazol-5-yl) -3-pyridinyl]phenyl]methyl] -2H- imidazol-2-one. The term "hydrido" denotes a single hydrogen atom (H) . This hydrido group may be attached, for example, to an oxygen atom to form a hydroxyl group; or, as another example, one hydrido group may be attached to a carbon atom to form a .CH— group; or, as another example, two hydrido groups may be attached to a carbon atom to form a -CH - group. Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about five carbon atoms. The term "cycloalkyl" embraces cyclic radicals having three to about ten ring carbon atoms, preferably three to about six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "haloalkyl" embraces radidals wherein any one or more of the alkyl carbon atoms is substituted with one or more halo groups, preferably selected from bromo, chloro and fluoro. Specifically embraced by the term "haloalkyl" are monohaloalkyl, dihaloalkyl and polyhaloalkyl groups. A monohaloalkyl group, for example, may have either a bromo, a chloro, or a fluoro atom within the group. Dihaloalkyl and polyhaloalkyl groups may be substituted with two or more of the same halo groups, or may have a combination of different halo groups. A dihaloalkyl group, for example, may have two fluoro atoms, such as difluoromethyl and difluoKobutyl groups, or two chloro atoms, such as a dichloromethyl group, or one fluoro atom and one chloro atom, such as a fluoro-chloromethyl group. Examples of a polyhaloalkyl are trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl and 2,2,3,3-tetrafluoropropyl groups. The term "difluoroalkyl" embraces alkyl groups having two fluoro atoms substituted on any one or two of the alkyl group carbon atoms. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy group. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy groups attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl groups. The "alkoxy" or "alkoxyalkyl" radicals may be further substi-tuted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl groups. The terms "benzyl" and "phenylmethyl" are interchangeable. For any of the foregoing defined radicals, preferred radicals are those containing from one to about ten carbon atoms. The term "arylheteroarylalkyl" embraces moieties, having an aryl fragment, a heteroaryl fragment and an alkyl fragment, of the type exemplified by moieties shown for the "A" substituent of Formula I, herein. Specific examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, methylbutyl, dimethylbutyl and neopentyl. Compounds of Formula I have been found to inhibit the action of angiotensin II in mammals. Angiotensin II is a potent vasoconstrictor and participates in the formation of aldosterone which regulates sodium and water balance in mammals. Thus, compounds of Formula I are therapeutically useful in methods for treating hypertension by administering to a hypertensive patient a therapeutically-effective amount of a compound of Formula I. The phrase "hypertensive patient" means, in this context, a mammalian subject suffering from or afflicted by the effects of hypertension or susceptible to a hypertensive condition if not treated to prevent or control such hypertension. Also included in the family of compounds of Formula I are isomeric forms including diastereoisomers and the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, salicyclic, phenylacetic, mandelic, embonic (pamoic) , methansulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, β-hydroxybutyric, malonic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylgluca- mine) and procaine. All of these salts may be prepared by conventional means from thecorresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I. General Synthetic Procedures The compounds of the invention can be synthesized according to the following procedures of Schemes I-XXIX, wherein the R substituents are as defined for Formula I, above, except where further noted. Scheme I 1. n-BuLi, THF, -78° C 2. B(OCH 3 ) 3 3. H 3 O + [R 6 =CON(CH 3 )C(CH 3 ) 3 ] Synthet c Scheme I shows the preparation of the boronic acid 1 where R 6 equals N-tertbutyl-N- methylcarboxamide. In step 1, benzoic acid is treated with thionyl chloride to give the corresponding acid chloride which is subsequently reacted with N-tertbutyl- N-methylamine to give N-tertbutyl-N-methylbenzamide. In step 2, the amide is ortho-metalated and subsequently reacted with trimethyl borate. The free boronic acid 1 is produced on hydroylsis. Scheme II 2 H 5 ) 3 [R 6 =CN 4 C(C 6 H 5 ) 3 ] Synthetic Scheme II shows the preparation of the boronic acid 1 where R 6 equals N-triphenylmethyl-lH- tetrazole. In step 1, 2-bromobenzonitrile (Aldrich) is reacted with tributyltin azide to give the corresponding tetrazole. In step 2, the tetrazole is reacted with triphenylmethyl chloride in the presence of triethylamine to give the protected bromophenyltetrazole. In step 3, halogen-metal interchange with n-butyllithium generates the corresponding ortho-lithiated species which is reacted with trimethyl borate. The free boronic acid -1 is produced on hydrolysis. Scheme III O R 5 O II I II (CH 3 ) 3 C-0-C-N-C— O— OH H H 3 1. Cl-CO-OCH 2 CH(CH 3 ) 2 N(C 2 H 5 ) 3 , CH 2 C1 2 , 0 ° CH, H- N O-CH, O R 5 O CH, (CH 3 ) 3 C-0-C-N-C— C— N O-CH, H H R 4 -Li 0 R 5 O II I II (CH 3 ) 3 C-0-C-N-C— C— R 4 H H Synthetic Scheme III shows the preparation of N-Boc-amino ketones 2. (or aldehydes when R^ = H) from the corresponding N-Boc-amino acides _. In step 1, the amino acid 3_ is reacted with isobutyl chloroformate in the presence of triethylamine and subsequently with N,0- dimethylhydroxylamine to give the corresponding N- methoxy-N-methylamide ±. In step 2, the amide 4. is reacted with an organolithium reagent R 4 -Li (or lithium aluminum hydride (LAH) when R 4 = H) to give the desired ketone 2 (or aldehyde when R 4 = H) . Scheme IV METHOD A: O R 5 O R 5 O CH, TFA CH, (CH 3 ) 3 C-0-C-N-C— C— N TFA:H 2 N-C— 0— N I I 0-CH 3 CH 2 C1 2 O-CH 3 H H H Synthetic Scheme IV shows the preparation of imidazol-2-ones 5_ from the corresponding amides 4. via Method A. In step 1, the protected amide 4. (prepared in Scheme III) is reacted with trifluoroacetic acid (TFA) to give the TFA salt £ of the free amine. In step 2, the salt £. is reacted with the appropriate isocyanate 2 in the presence of triethylamine to give the urea £. In step 3, the urea £ is reacted with an organolithium reagent R 4 -Li (or lithium aluminum hydride (LAH) when R 4 = H) and subsequently cyclized to the imidazole-2-one jj. on treatment with dilute acid during the work-up procedure. Scheme V METHOD B: O R 5 O (CH 3 ) 3 C-0-C-N-C— C— R 4 H H 2 HQ, dioxane Synthetic Scheme V shows the preparation of imidazol-2-ones jj. from the corresponding N-Boc-protected amino ketones 2. (or aldehydes when R 4 = H) via Method B. In step 1, the carbonyl compound 2. (prepared in Scheme III) is reacted with anhydrous hydrogen chloride in dioxane to give the HCl salt -£. In step 2, the salt 9_ is reacted with the appropriate isocyanate 7. in chloroform to give the imidazol-2-one 5. directly. Scheme VI METHOD C: (CH 3 ) 3 Synthetic Scheme VI shows the preparation of imidazol-2-ones -5. from the corresponding N-Boc-protected amino ketones 2. (or aldehydes when R 4 = H) via Method C. In step 1, the carbonyl compound 2. (prepared in Scheme III) is reacted with 2,2-dimethyl-l,3-propandiol to give the cyclic ketal -1&. In step 2, the ketal -lϋ is reacted with TFA to give the TFA salt H of the free amine. In step 3, the salt H is reacted with the appropriate isocyanate 2 n the presence of triethylamine to give the urea ketal 12.- In step 4, the urea ketal 12. is reacted with 6N hydrochloric acid at 60°C to give the desired imidazol-2-one ≤, directly. Scheme VII KMnO 4 1. Cl-CO-OCH 2 CH(CH 3 ) 2 N(C 2 H 5 ) 3 ,CH 2 C1 2 ,0°C 2. HN(CH 3 )OCH 3 3. LAH Synthetic Scheme VII shows the preparation of 2-bromomethyl-5-bromopyridine (12.) and 5-bromo-2- pyridinecarboxaldehyde (14.) from 2-picoline (Aldrich) . In step 1, 2-picoline is reacted with bromine in the presence of a large excess of aluminum chloride at elevated temperatures to give 5-bromo-2-picoline (13.) . In step 2a, l≤. is reacted with NBS to give the 2- pyridinylmethyl bromide 12. In step 2b, the intermediate l≥. is treated with potassium permanganate to give the corresponding picolinic acid 1 . In step 3b, the acid 1£ is first converted to its N-methoxy-N- methylamide and subsequently reduced with LAH to provide 5-bromo-2-pyridinecarboxaldehyde (2A) • Scheme VIII KMnO, 1. Cl-CO-OCH 2 CHCH 3 ) 2 N(C 2 H 5 ) 3 ,CH 2 Cl 2 ,0 o C 2. HN(CH 3 )OCH 3 3. LAH 18 Synthetic Scheme VIII shows the preparation of 2-bromo-5-bromomethylpyridine (12) and 2-bromo-5- pyridinecarboxaldehyde (l≤.) from 2-amino-5-picoline (Aldrich) . In step 1, 2-amino-5-picoline is reacted with bromine in the presence of hydrobromic acid and sodium nitrite at 0°C to give 2-bromo-5-picoline (12.) . In step 2a, 12. is reacted with NBS to give the 3- pyridinylmethyl bromide 12- In step 2b, the intermediate 12. is treated with potassium permanganate to give the corresponding nicotinic acid 2SL- In step 3b, the acid 2D. is first converted to its N-methoxy-N- methylamide and subsequently reduced with LAH to provide 2-bromo-5-pyridinecarboxaldehyde (23.) • Scheme IX Synthetic Scheme IX shows the preparation of (4-bromobenzyl) imidazol-2-ones 21 from the TFA salt of the amino amide £ (prepared in Scheme III) . In step 1, the TFA salt jj. is allowed to react with the 4- bromobenzaldehyde in the presence of triethylamine and anhydrous magnesium sulfate to give the i ine 22.- I step 2, the imine 22. is allowed to react with sodium borohydride to give the substituted benzylamine 22.- In step 3, the benzylamine 22. is allowed to react with the appropriate isocyanate 2 to give the substituted benzylurea 2 - In step 4, the urea 2A is first allowed to react with an organolithium reagent R 4 -Li (or lithium aluminum hydride (LAH) when R 4 = H) and subsequently with dilute aqueous acid to give the desired 3-(4-bromobenzyl)imidazol-2-ones. Scheme X TFA:H 2 N — NaBH_ Synthetic Scheme X shows the preparation of 3-(5-bromo-2-pyridinylmethyl)imidazol-2-ones 22. from the TFA salt of the amino amide £ (prepared in Scheme III) . In step 1, the TFA salt £ is allowed to react with the 5-bromo-2-pyridinylaldehyde 14 (prepared in Scheme VII) in the presence of triethylamine and anhydrous magnesium sulfate to give the imine 2£- In step 2, the imine 2£ is allowed to react with sodium borohydride to give the substituted benzylamine 22- In step 3, the benzylamine 22 is allowed to react with the appropriate isocyanate 2 to give the substituted benzylurea 2__- In step 4, the urea 22. is first allowed to react with an organolithium reagent R -Li (or lithium aluminum hydride (LAH) when R 4 = H) and subsequently with dilute aqueous acid to give the desired 3- (5-bromo-2-pyridinylmethyl) imidazol-2-ones 22- Scheme XI Synthetic Scheme XI shows the preparation of 3-(2-bromo-5-pyridinylmethyl)imidazol-2-ones 22. from the TFA salt of the amino amide £ (prepared in Scheme III) . In step 1, the TFA salt £ is allowed to react with 2- bromo-5-pyridinylaldehyde 22 (prepared in Scheme VIII) in the presence of triethylamine and anhydrous magnesium sulfate to give the imine 22• In step 2, the imine 22 is allowed to react with sodium borohydride to give the substituted benzylamine 21- In step 3, the benzylamine 21 is allowed to react with the appropriate isocyanate 2 to give the substituted benzylurea 22- In step 4, the urea 2 is first allowed to react with an organolithium reagent R 4 -Li (or lithium aluminum hydride (LAH) when R 4 = H) and subsequently with dilute aqueous acid to give the desired 3- (2-bromo-5-pyridinylmethyl) imidazol-2-ones 22- Scheme XII Synthetic Scheme XII shows the preparation of 3-(4-bromobenzyl)imidazc ' ..-2-ones 21/ 3- (5-bromo-2- pyridinylmethyl)imidazol-2-ones 22 and 3-(2-bromo-5- pyridinylmethyl)imidazol-2-ones 22. from the parent imidazol-2-ones 2 (prepared in Scheme IV, Scheme V, or Scheme VI) . The imidazol-2-one is first treated with a base, such as potassium £.-butoxide, and subsequently with the alkylating agent 4-bromobenzyl bromide, 13 (prepared in Scheme VII) , and 12 (prepared in Scheme VIII) to give 3-(4-bromobenzyl)imidazol-2-ones 21, 3- (5-bromo-2- pyridinylmethyl)imidazol-2-ones 22> and 3-(2-bromo-5- pyridinylmethyl)imidazol-2-ones 22> respectively. Scheme XIII 30 Synthetic Scheme XIII shows the preparation of 3-[[5-[2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- 2H-imidazol-2-ones 22 from the boronic acid 1 (prepared in Scheme I and Scheme II) and the bromoimidazol-2-one coupling reagent 2 (prepared in Scheme X and Scheme XII) . The boronic acid 1 is reacted with the bromoimidazol-2-one coupling reagent 22 in the presence of a palladium zero catalyst via a Snieckus coupling [see M. J. Sharp and V. Snieckus, Tetrahedron Lett... 5997(1985)] to give the angiotensin II antagonists 22 of this invention. Scheme XIV 31 Synthetic Scheme XIV shows the preparation of 3-[ [6-[2- (IH-tetrzol-5-yl)phenyl]-3-pyridinyl]methyl] - 2H-imidazol-2-ones 21 from the boronic acid 1 (prepared in Scheme I and Scheme II) and the bromoimidazol-2-one coupling reagent 22. (prepared in Scheme XI and Scheme XII) . The boronic acid 1 is reacted with the bromoimidazol-2-one coupling reagent 22 in the presence of a palladium zero catalyst via a Snieckus coupling [see M. J. Sharp and V. Snieckus, Tetrahedron Lett. , 5997(1985)] to give the angiotensin II antagonists 21 of this invention. Scheme XV Synthetic Scheme XV shows the preparation of the imidazol-2-one boronic acid coupling reagents . from the corresponding 3-(4-bromobenzyl)imidazol-2-ones 21 (prepared in Scheme IX and Scheme XII) . Halogen- metal interchange generates the corresponding lithiated species from 21 which is reacted with trimethyl borate. The free imidazol-2-one boronic acid coupling reagents 32 are produced on acid hydrolysis. Scheme XVI 1. SOCl 2 2. HN(CH 3 )C(CH 3 ) 3 C 33 34 [R 6 =CON(CH 3 )C(CH 3 ) 3 ] [R 6 =CON(CH 3 )C(CH 3 ) 3 ] Synthetic Scheme XVI shows the preparation of the 4-bromopyridine coupling reagent 22. [R 6 = CON(CH 3 )C(CH 3 ) 3 ] and the 2-bromopyridine coupling reagent 34 [R 6 = CON(CH 3 )C(CH 3 ) 3 ] from nicotinic acid. In step 1, N-tertbuty-N-methylnicotinamide is prepared from nicotinoyl chloride and N-tertbutyl-N-methylamine. In step 2, ortho-metalalion with sec-butyllithium gives a mixture of regioanions which are reacted with trimethylsilyl chloride; subsequent conversion to the corresponding bromides on treatment with bromine in acetic acid and separation of the regioisomers by chromatography provides 22 and 34. Scheme XVII 1. SOCl 2 2. HN(CH 3 )C(CH 3 ) 3 3 ) 3 1. sec-BuLi, TMEDA, THF, -78° C 2. (CH 3 ) 3 Si-Cl 3. Br 2 , AcOH 3 ^ 3 35 [R 6 =CON(CH 3 )C(CH 3 ) 3 ] Synthetic Scheme XVII shows the preparation of the 3-bromopyridine coupling reagent 22 [R 6 = CON(CH 3 )C(CH 3 ) 3 ] from isonicotinic acid. In step 1, N-tertbutyl-N-methylisonicotinamide is prepared from isonicotinoyl chloride and N-tertbutyl-N-methylamine. In step 2, reaction with sec-butyllithium gives the ortho-lithiated species which is reacted with trimethylsilyl chloride and subsequently converted to the corresponding bromide 22 on treatment with bromine in acetic acid. Scheme XVIII 1. SOCl 2 2. HN(CH 3 )C(CH 3 ) 3 3 ) 3 1. sec-BuLi, TMEDA, THF, -78° C 2. (CH 3 ) 3 Si-Cl 3. Br 2 , AcOH 36 [R 6 =CON(CH 3 )C(CH 3 ) 3 ] Synthetic Scheme XVIII shows the preparation of the 3-bromopyridine coupling reagent 2£ [R 6 = CON(CH 3 )C(CH 3 ) 3 ] from picolinic acid. In step 1, N-tertbutyl-N-methylpicolinamide is prepared from picolinoyl chloride and N-tertbutyl-N-methylamine. In step 2, reaction with sec-butyllithium gives the ortho- lithiated species which is reacted with trimethylsilyl chloride and subsequently converted to the corresponding bromide 2 on treatment with bromine in acetic acid. Scheme XIX Synthetic Scheme XIX shows the preparation of 3-(pyridinylbenzyl)imidazol-2-ones 22, 38. 39 and 40 from the common imidazol-2-one boronic acids 22 (Scheme XV) and the corresponding bromo coupling reagents 2£ (Scheme XVIII), 22 (Scheme XVI, 22 (Scheme XVII), and 21 (Scheme XVI) , respectively. The boronic acids 22 are reacted with the bromo coupling reagents 2£# 22/ 22 and 34 in the presence of a palladium zero catalyst via a Snieckus coupling [see M. J. Sharp and V. Snieckus, Tetrahedron Lett.. 5997 (1985)] to give the angiotensin II antagonists 22, 22/ 22. and 1 / respectively, of this invention. Scheme XX 1. KOH, Δ 2. H 3 O + o P(C 6 H 5 ) 3 II 1. (COCl) 2 R-CN R-C-NH 2 R-C-OH CC1 4 , 50 ° C 2. NH 3 47 46 41 (CH 3 ) 3 SnN 3> xylene, Δ 42 Synthetic Scheme XX shows the preparation of carboxylic acid analogs ϋ and lH-tetrazole analogs 42 from analogs which have R 6 = CON(CH 3 )C(CH 3 ) 3 . In step 1, the N-tertbutyl-N-methylamide analog 12 is reacted with trifluoroacetic acid at reflux to give the N-methylamide 44. In step 2, the N-methylamide ϋ is reacted with sodium nitrite in acetic anhydride/acetic acid at 0°C to give the corresponding N-methyl-N-nitrosoamide - In step 3, the N-methyl-N-nitrosoamide 12 is hydrolyzed in base to give the corresponding carboxylic acid angiotensin II antagonists of this invention. In step 4, the acid analog ϋ is reacted with oxalyl chloride and subsequently with anhydrous ammonia to give the primary amide !£. In step 5, the amide !£ is reacted with triphenylphosphine in carbon tetrachloride at 50°C to give the corresponding nitrile 12- In step 6, the nitrile 12 is reacted with trimethyltin azide in xylene at reflux to provide the lH-tetrazole angiotensin II antagonists of this invention. Scheme XXI 51 ZnCI, 48 R 6 = CO 2 R, CN, CN 4 C(C 6 H 5 ) 3 , or CN 4 H Synthetic Scheme XXI shows the preparation of the organozinc reagent.12 from the appropriate benzoic acid analog 2- In step 1, the analog 1 is bro inated with bromine in the presence of a suitable catalyst, e.g., iron, to give the 2-bromo analog 22- In step 2, the 2-bromo analog ^ was converted to the organolithium reagent 21 by reaction with n-butyllithium in THF at -78°C, a process known as halogen-metal interchange. Alternatively, the organolithium reagent 21 can be generated directly by the reaction of 12 with an alkyllithium reagent in the presence or absence of a suitable complexing agent in THF at -78°C, e.g., sec- butyllithium/TMEDA (N,N,N' ,N'-tetramethyl- ethylenediamine) . In step 3, the organolithium reagent 21 was treated with anhydrous zinc chloride at -78°C and subsequently allowed to warm to ambient temperature. The organozinc reagent 12 was generated and used in situ. Scheme XXII NBS, AIBN CC1 4 , Δ 53 Synthetic Scheme XXII shows the preparation of the 2-pyridinyl alkylating reagent 22 and the 3- pyridinyl alkylating 22 from 12 (Scheme VII) and 19 (Scheme VIII) , respectively. In step 1, 12 and 1 were coupled with 1 using Snieckus conditions (Scheme XIII) or 12 using Negishi conditions [see E. Negishi, A. 0. King, and N. Okukado, J. Orσ. Chem.. 42. 1821 (1977)] to give 3 and 22/ respectively. In step 2, the coupled biaryl compounds 21 and 22 were brominated using NBS/AIBN to give the 2-pyridinyl alkylating reagent 52 and the 3-pyridinyl alkylating reagent ^2, respectively. Scheme XXIII 31 Synthetic Scheme XXIII shows the preparation of 3-[[5-[2-(lH~tetrazol-5-yl)phenyl]-2- pyridinyl]methyl] -2H-imidazol-2-ones 22 (R 6 =CN 4 H) and 3- [ [6-[2- (lH-tetrazol-5-yl) henyl] -3-pyridinyl]methyl] -2H- imidazol-2-ones 21 (R 6 =CN 4 H) from the parent imidazol-2- ones 2 (prepared in Scheme IV, Scheme V, or Scheme VI) . The imidazol-2-one was first treated with a base, such as potassium £.-butoxide, and subsequently with the alkylating reagent 22 or 22 (Scheme XXII) to give 3-[[5- [2-(lH-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2H- imidazol-2-ones 22 (R δ =CN 4 H) and 3-[ [6-[2-(lH-tetrazoi-5- yl)phenyl] -3-pyridinyl]methyl]-2H-imidazol-2-ones 21 (R 6 =CN 4 H) , respectively. Scheme XXIV Synthetic Scheme XXIV shows the preparation of 4-methylphenylboronic acid (2£) from 4-bromotoluene. In step 1, the Grignard reagent was generated by the reaction of 4-bromotoluene with metallic magnesium in ether at reflux. In step 2, a THF solution of trimethoxyborane was cooled to -78° C and slowly treated with the Grignard reagent. In step 3, the boronic ester was hydrolyzed with aqueous hydrochloric acid to give 4- methylphenylboronic acid (22) • Scheme XXV 58 59 60 BH 3 , THF 63 62 61 Ac 2 O, Δ 65 57 Synthetic Scheme XXV shows the 8-step preparation of the alkylating reagent 2-(4- bromomethyIphenyl)-3-cyanopyridine (22) from 2-amino-3- picoline (22) (Aldrich) . In step 1, the aminopicoline 22 was converted to the bromopicoline 22 by reaction with bromine, concentrated hydrobromic acid, and sodium nitrite at 0°C. In step 2, the picoline 22 was oxidized with KMN0 4 to give the corresponding carboxylic acid 60. In step 3, the acid £2 was reduced to the alcohol £1 with borane/THF. In step 4, the alcohol £1 was oxidized to the aldelyde £2 under Swern conditions or by using Mn0 2 . In step 5, the aldehyde £2 was reacted with hydroxylamine to give the oxime £2. In step 6, the oxime 63 was converted to 2-bromo-3-cyanopyridine (£1) with acetic anhydride at reflux. In step 7, the nitrile £1 was coupled with 4-me hylphenylboronic acid (££) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 3- cyano-2-(4-methyIphenyl)pyridine (£2). In step 8, £2 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 57. Scheme XXVI 67 68 69 1. (COCl) 2 2. NH 3 71 70 Snieckus Coupling 56 72 66 Synthetic Scheme XXVI shows the 6-step preparation of the alkylating reagent 3-(4- br momethyIphenyl) -4-cyanopyridine (££) from 4-picoline (67) (Aldrich) . In step 1, 4-picoline was brominated with bromine in fuming sulfuric acid at high temperatures to give 3-bromo-4-picoline (£2)- In step 2, the picoline £2 was oxidized to the corresponding carboxylic acid £2 with KMn0 4 . In step 3, the acid £2 was first converted to its acid chloride with oxalyl chloride and subsequently treated with condensed ammonia to give the amide 22- In step 4, the amide 22 was converted to 3-bromo-4-cyanopyridine (21) by treatment with P0 5 at high temperatures. In step 5, the nitrile 71 was coupled with 4-methylphenylboronic acid (56) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 4-cyano-3- (4-methyIphenyl)pyridine (22)- In step 6, 72 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 66. Scheme XXVII Synthetic Scheme XXVII shows the 5-step preparation of the alkylating reagent 4- (4- bromomethyIphenyl)-3-cyanopyridine (22) from 4- bromopyridine (21) (Aldrich) . In step 1, the ortho-bromo carbanion was generated with LDA in THF at -78° C and reacted with anhydrous DMF to give 4-bromo-3- carboxaldehyde 22- In step 2, the aldehyde 22 was reacted with hydroxylamine to give the oxime 7£. In step 3, the oxime 2£ was dehydrated with 1,1 ' - carbonyldiimidazole in methylene chloride at reflux to give 4-bromo-3-cyanopyridine (22) • In step 4, the nitrile 22 was coupled with 4-methylphenylboronic acid (2£) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 3-cyano-4-(4-methyIphenyl)pridine (78) . In step 5, 22 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 73. Scheme XXVIII 80 81 , 83 NBS, AIBN, CC1 4 , Δ 79 Synthetic Scheme XXVIII shows the 4-step preparation of the alkylating reagent 2-cyano-3- (4- bromomethyIphenyl)pyridine (22) from 3-bromopyridine (80) (Aldrich) . In step 1, the pyridine 22 was reacted with hydrogen peroxide in acetic acid at reflux to give the pyridine N-oxide 21- In step 2, the N-oxide 21 was converted to 3-bromo-2-cyanopyridine (^ ) by reaction with trimethysilylcyanide and triethyl anine in acetonitrile at reflux. In step 3, the nitrile 22 was coupled with 4-methylphenylboronic acid (££) (Scheme XXIV) using Snieckus conditions (Scheme XIII) to give 2- cyano-3-(4-methyIphenyl) pyridine (£2). In step 4, ^2 was brominated with NBS/AIBN in carbon tetrachloride at reflux to give the desired alkylating reagent 79. Scheme XXIX Synthetic Scheme XXIX shows the preparation of 1,4,5-trisubstituted-1,3-dihydro-3-[ [4- (2-cyano-3- pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 22. (R 6 =CN) , 1,4,5-trisubstituted-1,3-dihydro-3-[ [4- (3-cyano-4- pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 22 (R 6 =CN) , 1,4,5-trisubstituted-l,3-dihydro-3- [ [4- (4-cyano-3- pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 22 (R 6 =CN) , and 1,4,5-trisubstituted-l,3,-dihydro-3-[ [4-(3-cyano-2- pyridinyl)phenyl]methyl]-2H-imidazol-2-ones 12 (R 6 =CN) from the parent 1,4,5-trisubstituted-l,3-dihydro-2H- imidazol-2-ones 2 (prepared in Scheme IV, Scheme V, or Scheme VI). The imidazol-2-one 2 was first treated with a base, such as potassium £.-butoxide, and subsequently with the alkylating reagents 22 (Scheme XXVIII), 22 (Scheme XXVII), ££ (Scheme XXVI), and 22 (Scheme XXV) to give the alkylated products 22 (R 6 =CN) , 22 (R 6 =CN, 2 (R 6 =CN) , and 12 (R 6 =CN) , respectively. The following Examples contain detailed descriptions of the methods of preparation of compounds of Formula I. These detailed descriptions fall within the scope of, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are no intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in degrees Centigrade, unless otherwise indicated. l-phenyl-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5-yl)phenyI]- 3-pyridinyl]methyl]-2H-imidazol-2-one Step 1: Preparation of l-ohenvl-4-butvl-l.3-dihvdro- 2H-imidazol-2-one. Following General Synthetic Schemes III and IV, l-phenyl-4-butyl-l,3-dihydro-2H-imidazol-2-one was prepared: NMR (CDC1 3 ) δ 0.93 (t, J=7 Hz, 3H) , 1.39 (m, 2=7 Hz, 2H) , 1.59 (m, 2=7 Hz, 2H) , 2.42 (td, 2=8 and 1 Hz, 2H) , 6.26 (t, 2=1 Hz, IH) , 7.21 (t, 2=7 Hz, IH) , 7.41 (t, 2=8 Hz, 2H) , 7.57-7.62 (m, 2H) , 10.28 (br s, IH) ; MS (FAB) m/e (rel intensity) 217 (100), 201 (2), 187 (3), 173 (11); HMRS: Calc'd for M+H: 217.1341. Found: 217.1309. Step 2: Preparation of l-phenvl-4-butvl-l.3-dihvdro-3- r ffi- T2- (lH-tetrazol-5-vl)phenvll -3-pyridinyllmethyll -2H- imJdazol-2-one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1-phenyl-4-butyl-1,3-dihydro-3-[ [6-[2-(lH-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one as a colorless solid: NMR (CDC1 3 ) δ 0.91 (t, 2=7 Hz, 3H) , 1.40 (m, 2=7 Hz, 2H) , 1.55 (m, 2=7 Hz, 2H) , 2.39 (t, 2=7 Hz, 2H) , 5.05 (s, 2H) , 6.38 (s, IH) , 7.20-7.26 (m, IH) , 7.34-7.56 (m, 6H) , 7.59-7.66 (m, 2H) , 7.85 (dd, 2=8 and 2 Hz, IH) , 7.97-8.03 (m, IH) , 8.58 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 452 (51), 424 (23), 409 (7), 237 (13), 217 (13), 209 (100), 208 (67), 194 (38), 193 (38); HMRS: Calc'd for M+H: 452.2199. Found: 452.2248. Example 2 l-(2-chlorophenyI)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazoI-5- yl)phenyI]-3-pyridinyI]methyI]-2H-imidazoI-2-one Step 1: Preparation of 1- ( 2-chlorophenyl) -4-butvl-1.3- dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2-chlorophenyl) -4-butyl-l,3-dihydro-2H-imidazol- 2-one was prepared: NMR (CDC1 3 ) δ 0.90 (t, 2=7 Hz, 3H) , 1.36 (m, 2=7 Hz, 2H) , 1.54 (m, 2=7 Hz, 2H) , 2.37 (t, 2=7 Hz, 2H) , 6.06 (br ε, IH) , 7.23-7.38 (m, 2H) , 7.41-7.53 (m, 2H) , 10.29 (br s, IH) ; MS (FAB) m/e (rel intensity) 252 (36) , 250 (100) . Ste , Preparation of 1- (2-chlorophenyl) -4-butvl-l. - dihvdro-3-rr6-r2-(lH-tetrazol-5-vl)phenvlA3- nvridinv-1 lmethvl1-2H-imidazol-2-one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to l-(2-chlorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one as a colorless solid: mp 81-83° C; NMR (CDC1 3 ) δ 0.90 (t, 2=7 Hz, 3H) , 1.39 (m, 2=7 Hz, 2H) , 1.54 (m, 2=7 Hz, 2H) , 2.37 (td, 2=8 and 1 Hz, 2H) , 5.03 (s, 2H) , 6.19 (t, 2=1 Hz, IH) , 7.31-7.37 (m, 2H) , 7.46-7.63 (m, 6H) , 7.88 (dd, 2=8 and 2 Hz, IH) , 8.15-8.21 (m, IH) , 8.65 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 488 (15), 486 (37), 460 (5), 458 (8); HMRS: Calc'd for M+H: 486.1809. Found: 486.1781. Example 3 l-(2-methylphenyl)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5- yl)phenyl]-3-pyridinyl]methyI]-2H-imidazol-2-one Step 1: Preparation of 1- .2-π.ethvlphenvl) -4-butyl-l.3- dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2-methylphenyl) -4-butyl-l,3-dihydro-2H-imidazol- 2-one was prepared: NMR (CDC1 3 ) δ 0.92 (t, 2=7 Hz, 3H) , 1.37 (m, 2=7 Hz, 2H) , 1.55 (m, 2=7 Hz, 2H) , 2.28 (s, 3H) , 2.39 (td, 2=7 Hz, 2H) , 5.96-5.99 (m, IH) , 7.21-7.31 (m, 4H) , 9.88 (br s, IH) ; MS (FAB) m/e (rel intensity) 231 (100), 201 (2), 175 (2), 155 (3), 127 (4), 106 (3); HMRS: Calc'd for M+H: 231.1497. Found: 231.1448. Step 2: Preparation of 1- (2-me hvlphenyl) -4-butyl-l.3- .hv rn-3- r ffi- .2- (lH-tetrazol-5-yl)phenv!1 -3- pvridinvl1mftt.-_vl.-2H-imidazol- -one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1- (2-methyIphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one as a colorless solid: NMR (CDC1 3 ) δ 0.89 (t, 2=8 Hz, 3H), 1.31-1.45 (m, 2H) , 1.46-1.59 (m, 2H) , 2.26 (s, 3H) , 2.37 (td, 2=8 and 1 Hz, 2H) , 5.05 (ε, 2H) , 6.10 (t, 2=1 Hz, IH) , 7.22-7.31 (m, 4H) , 7.37 (d, 2=8 Hz, IH) , 7.48- 7.59 (m, 3H) , 7.81 (dd, 2=8 and 2 Hz, IH) , 7.98-8.05 (m, IH) , 8.57 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 466 (64), 438 (23), 237 (25), 231 (33), 209 (100), 194 (37), 193 (32), 180 (83); HMRS: Calc'd for M+H: 466.2355. Found: 466.2397. Example 4 l-(2-methoxyphenyI)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazoI-5- yl)phenyl]-3-pyridinyl]methyI]-2H-imidazol-2-one Step 1: Preparation of 1- (2-methoxyphenyl) -4-butvl- 1. -dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2-methoxyphenyl) -4-butyl-l,3-dihydro-2H-imidazol- 2-one waε prepared: NMR (CDC1 3 ) δ 0.91 (t, 2=7 Hz, 3H) , 1.37 (m, 2=7 Hz, 2H) , 1.56 (m, 2=7 Hz, 2H) , 2.40 (td, 2=8 and 1 Hz, 2H) , 3.83 (ε, 3H) , 6.08-6.12 (m, IH) , 6.96-7.04 (m, 2H) , 7.29 (td, 2=8 and 2 Hz, IH) , 7.43 (dd, 2=8 and 2 Hz, IH) , 9.94 (s, IH) ; MS (FAB) m/e (rel intensity) 247 (100), 217 (3), 203 (7); HMRS: Calc'd for M+H: 247.1447. Found: 247.1470. Step 2: Preparation of 1- (2-methoxyphenyl) -4-butyl- 1 ■3-dihvdro-3-rr6-r2-(lH-tetrazol-5-yl)phenyl1-3- pyridinvl1methvlA2H-imidazol-2-one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1-(2-methoxyphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one as a colorless solid: NMR (CDC1 3 ) δ 0.91 (t, 2=7 Hz, 3H) , 1.40 (m, 2=7 Hz, 2H) , 1.53 (m, 2=7 Hz, 2H) , 2.40 (t, 2=7 Hz, 2H) , 3.83 (s, 3H) , 5.06 (s, 2H) , 6.20 (ε, IH) , 6.96-7.03 (m, 2H) , 7.27-7.34 (m, 3H) , 7-42 (dd, 2=8 and 2 Hz, IH) , 7.53-7.65 (m, 4H) , 8.09-8.17 (m, 2H) , 8.66 (ε, IH) ; MS (FAB) m/e (rel intensity) 482 (67), 454 (20), 439 (5), 247 (40), 237 (22), 209 (100), 208 (66), 194 (38), 193 (31); HMRS: Calc'd for M+H: 482.2304. Found: 482.2324. Example 5 l-(2-ethyIphenyl)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5- yI)phenyI]-3-pyridinyl]methyl]-2H-imidazoI-2-one __1≤D_1: Preparation of 1- .2-ethvlphenvl) -4-butvl-l.3- dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1-(2-ehtyIphenyl)-4-butyl-l,3-dihydro-2H-imidazol-2- one was prepared: NMR (CDC1 3 ) δ 0.92 (t, 2=7 Hz, 3H) , 1.17 (t, 2=7 Hz, 3H) , 1.38 (m, = 7 Hz, 2H) , 1.58(m, 2=7 Hz, 2H) , 2.46 (t, 2=7 Hz, 2H) , 2.58 (q, 2=7 Hz, 2H) , 6.06 (s, IH) , 7.16-7.30 (m, 2H) , 7.30-7.40 (m, 2H) . Step 2: Preparation of 1- (2-ethvlphenvl)-4-butvl-l.3- dihvdro-3-rr6-r2-(lH-te razol-5-vl)phenyl1-3- nvridinvl1methvll-2H-imidazol-2-one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to l-(2-ethylphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H-imidazol-2- one as a colorlesε εolid: mp 151-152° C; NMR (CDCl 3 )δ 0.91 (t, 2=8 Hz, 3H) , 1.17 (t, 2=8 Hz, 3H) , 1.33-1.43 (m, 2H) , 1.50-1.60 (m, 2H) , 2.41 (t, 2=7 Hz, 2H) , 2.60 (q, 2=8 Hz, 2H) , 5.07 (s,2H), 6.10 (s,lH), 7.22 (d, 2=3 Hz, 2H) , 7.34 (d, 2= 3 Hz, 2H) , 7.51 (d, 2=8 Hz, IH) , 7.55-7.65 (m,3H), 8.01(dd, 2=8 and 2 Hz, IH) , 8.06-8.13 (m,lH), 8.84 (br ε, IH) ; MS(FAB) m/e (rel intenεity) 480 (33), 452 (15), 424 (5), 243 (15), 237 (18), 209 (100), 180 (88), 152 (10), 130 (17); HMRS: Calc'd for M+H: 480.2512. Found: 480.2518. Example 6 l-(2-isopropylphenyl)-4-butyI-l,3-dihydro-3-[[6-[2-(lH-tetrazoI-5- yl)phenyI]-3-pyridinyI]methyI]-2H-imidazol-2-one Step 1 : Preparation of 1- (2-isopropvlphenvl ) -4-butvl- 1 . 3 -dihvdro-2H-imidazol-2-one . Following General Synthetic Schemes III and IV, 1- (2-isopropylphenyl)-4-butyl-l,3-dihydro-2H- imidazol-2-one was prepared: NMR (CDC1 3 ) δ 0.89 (t, J=7 Hz, 3H) , 1.21 (d, 2=7 Hz, 6H) , 1.30-1.44 (m, 2H) , 1.48- 1.60 (m, 2H) , 2.38 (t, 2=7 Hz, 2H) , 3.05 (m, 2=7 Hz, IH) , 5.93-5.96 (m, IH) , 7.17-7.42 (m, 4H) , 10.65 (br s, IH) ; MS (FAB) m/e (rel intenεity) 259 (100); HMRS: Calc'd for M+H: 259.1810. Found: 259.1799. Step 2: Preparation of 1-(2-isopropvlphenvl) -4-butvl- 1.3-dihvdro-3-r .6- \ 2- (lH-tetrazol-5-vl)phenvll-3- nvr-idinvl1methvπ-2H-imidazol-2-one. Following General Synthetic Sche eε XXII and XXIII, the imidazol-2-one from Step 1 waε converted to 1-(2-isopropylphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one as a colorless solid: NMR (CDC1 3 ) δ 0.89 (t, 2=7 Hz, 3H) , 1.21 (d, 2=7 Hz, 6H) , 1.37 (m, 2=7 Hz, 2H) , 1.52 (m, 2=7 Hz, 2H) , 2.36 (t, 2=7 Hz, 2H) , 2.98 (m, 2=7 Hz, IH) , 5.07 (s, 2H), 6.07 (s, IH) , 7.09-7.25 (m, 2H) , 7.30-7.43 (m, 3H) , 7.46-7.55 (m, 3H) , 7.81 (dd, 2=8 and 1 Hz, IH) , 7.92-7.99 (m, IH) , 8.53 (d, 2=1 Hz, IH) ; MS (FAB) m/e (rel intensity) 494 (75), 466 (26), 451 (4), 259 (14), 237 (37), 209 (100), 208 (61), 194 (37), 193 (32); HMRS: Calc'd for M+H: 494.2668. Found: 494.2651. Example 7 l-(2-tertbutyIphenyI)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazoI-5- yl)phenyI]-3-pyridinyl]methyI]-2H-imidazol-2-one Step 1 : Preparation of 1- ( 2 -tertbutvlphenvl ) -4 -but.vl - 1. 3 -dihydro-2H- imidazol-2-one . Following General Synthetic Schemes III and IV, 1- ( 2 -tertbutylphenyl ) -4-butyl-l , 3 -dihydro-2H- imidazol-2 -one was prepared : NMR (CDC1 3 ) δ 0 . 95 ( t , 2=8 Hz, 3H), 1.30 (s, 9H) , 1.35-1.45 (m, 2H) , 1.53-1.65 (m, 2H) , 2.50 (t, 2=8 Hz, 2H) , 6.12-6.14 (m, IH) , 7.05(dd, 2=8 and 2 Hz, IH) , 7.27 (td, 2=7 and 2 Hz, IH) , 7.57 (dd, 2=8 and 2 Hz, IH) . S ep 2: Preparation of 1-(2-tertbu vlphenvl)-4-butvl- 1.3-dihvdro-3-rr6-r2-(lH-tetrazol-5-vl)phenvπ-3- r.vri invllmethvπ-2H-imidazol-2-one. Following General Synthetic Schemeε XXII and XXIII, the imidazol-2-one from Step 1 waε converted to l-(2- tertbutyIphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one aε a colorless solid: NMR (CDC1 3 ) δ 0.85 (t, 2=7 Hz, 3H) , 1.30 (s, 9H) , 1.33-1.45 (m, 2H) , 1.45-1.58 (m, 2H) , 2.39 (t, 2=7 Hz, 2H) , 4.97(d, 2=16 Hz, IH) , 5.06 (d, 2=16 Hz, IH) , 6.07 (br s, IH) , 7.06 (dd, 2=7 and 2 Hz, IH) , 7.22 (td, 2=8 and 2 Hz, IH) , 7.35 (td, 2=8 and 2 Hz, IH) , 7.43 (d, 2=8 Hz, IH) , 7.50-7.61 (m, 4H) , 7.88- 7.92 (m, IH) , 8.03-8.08 (m, IH) , 8.61 (br s, IH) ; MS (FAB) m/e (rel intensity) 508 (40), 480 (20), 452 (5), 237 (20), 209 (100), 180 (85), 130 (15); HMRS: Calc'd for M+H: 508.2825. Found: 508.2792. Example 8 l-(2,6-difIuorophenyl)-4-butyI-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5- yl)phenyI]-3-pyridinyl]methyl]-2H-imidazol-2-one Step 1: Preparation of 1- (2.6-dif luorophenyl) -4-butvl- 1.3-dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- ( 2 , 6 -dif luorophenyl ) -4-butyl-l , 3 -dihydro- 2H- imidazol-2-one was prepared: NMR (CDC1 3 ) δ 0.93 (t, 2=7 Hz, 3H) , 1.31-1.46 (m, 2H) , 1.50-1.62 (m, 2H) , 2.41 (td, 2=8 and 1 Hz, 2H) , 6.05 (t, 2=1 Hz, IH) , 6.98-7.08 (m, 2H) , 7.27-7.39 (m, IH) , 9.18 (br ε, IH) . Step 2: Preparation of 1-(2. -difluorophenyl) -4-butvl- 1.3-dihvdro-3-rr6-r2-(lH-tetrazol-5-yl)phenylA3- Pvridinvl1methvlA2H-imidazol-2-one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1- (2,6-difluorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one as a colorlesε εolid: mp 164.5-165.5° C (dec); NMR (CDC1 3 ) δ 0.90 (t, 2=8 Hz, 3H) , 1.32-1.46 (m, 2H) , 1.48- 1.60 (m, 2H) , 2.37 (td, 2=8 and 1 Hz, 2H) 5.04 (s, 2H) , 6.14 (t, 2=1 Hz, IH) , 7.05 (t, 2=8 Hz, 2H) , 7.29-7.38 (m, IH) , 7.42 (d, 2=8 Hz, IH) , 7.48-7.58 (m, 3H) , 7.81 (dd, 2=8 and 2 Hz, IH) , 8.04-8.11 (m, IH) , 8.60 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 488 (83), 460 (26), 253 (10), 237 (25), 209 (100), 194 (37), 193 (35), 180 (80); HMRS: Calc'd for M+H: 488.2010. Found: 488.1951. Example 9 l-(2,6-dichlorophenyl)-4-butyI-l,3-dihydro-3-[[6-[2-(lH-tetrazoI-5- yl)phenyl]-3-pyridinyI]methyI]-2H-imidazoI-2-one Step 1: Preparation of 1- (2.6-di chlorophenyl ) -4-but.vl- 1.3-dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2, 6-dichlorophenyl) -4-butyl-l, 3-dihydro-2H- imidazol-2-one was prepared: NMR (CDC1 3 ) δ 0.93 (t, 2=7 Hz, 3H) , 1.32-1.46 (m, 2H) , 1.51-1.62 (m, 2H) , 2.43 (td, 2=8 and 1 Hz, 2H) , 5.94 (t, 2=1 Hz, IH) , 7.27-7.32 (m, IH) , 7.40-7.46 (m, 2H) , 9.33 (br s, IH) . Step 2: Preparation of 1- (2.6-dichlorophenyl) -4-butyl- 1. -(iihvdro-3-rr6-r2-(lH-tetrazol-5-vl)nhenv.11-3- pvridinvllmethvl1 -2H-imidazol-2-one. Following General Synthetic Schemeε XXII and XXIII, the imidazol-2-one from Step 1 waε converted to 1- (2 , 6-dichlorophenyl) -4-butyl-l,3-dihydro-3-[ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one as a colorlesε εolid: mp 212.0-212.5° C; NMR (CDC1 3 ) δ 0.88 (t, 2=8 Hz, 3H), 1.30-1.44 (m, 2H) , 1.47-1.59 (m, 2H) , 2.34 (td, 2=8 and 1 Hz, 2H) , 5.10 (s, 2H) , 6.04 (t, 2=1 Hz, IH) , 7.28-7.35 (m, 2H) , 7.42-7.55 (m, 5H) , 7.76 (dd, 2=8 and 2 Hz, IH) , 7.97-8.04 (m, IH) , 8.53 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 522 (48), 520 (85), 494 (8), 492 (12), 287 (4), 285 (8), 237 (51), 209 (93), 194 (35), 193 (31), 180 (95); HMRS: Calc'd for M+H: 520.1419. Found: 420.1443. Example 10 l-(2,6-dimethoxyphenyl)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazoI-5- yI)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one S e 1: Preparation of 1- (2. -dimethoχyphenyl) -4- hutvl-1.3-dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2, 6 -dimethy Iphenyl) -4-butyl-l, 3 -dihydro-2H- imidazol-2-one was prepared: NMR (DMSO-d 6 ) δ 0.89 (t, 2=8 Hz, 3H) , 1.27-1.40 (m, 2H) , 1.42-1.57 (m, 2H) , 2.26 (t, 2=8 Hz, 2H) , 3.71 (s, 6H) , 5.91 (t, 2=1 Hz, IH) , 6.72 (d, 2=8 Hz, 2H) , 7.31 (t, 2=8 Hz, 2H) , 9.85 (br ε, IH) . Step 2: Preparation of 1- (2.6-dimethoxyphenyl)-4- nn yl-1.3-dihvdro-3-rr6-r2- ( lH-tetrazol-5-yl)phenyll-3- pyridinyllmethyl] -2H-imidazol-2-one. Following General Synthetic Schemeε XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1- (2, 6-dimethoxyphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one as a colorless visious oil: NMR (DMSO-d 6 ) δ 0.82 (t, 2=7 Hz, 3H) , 1.21-1.44 (m, 4H) , 2.26 (t, 2=7 Hz, 2H) , 3.73 (s, 6H) , 4.86 (ε, 2H) , 6.10 (t, 2=1 Hz, IH) , 6.76 (d, 2=8 Hz, 2H) , 7.35(t, 2=8 Hz, IH) , 7.48 (d, 2=9 Hz, IH) 7.57-7.82 (m, 5H) , 8.25 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 512 (30), 484 (20), 180 (90); HRMS: Calc'd for M+H: 512.2410. Found: 512.2465. Example 11 l-(2-chloro-6-methyIphenyl)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5- yI)phenyl]-3-pyridinyl]methyl]-2H-imidazoI-2-one Step 1: Preparation of 1 - (2-chloro-6-methylvphenyl) -4- butvl-1.3-dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2-chloro-6-methylyphenyl) -4-butyl-l, 3-dihydro-2H- imidazol-2-one waε prepared: NMR (CDCl 3 ) δ 0.90 (t, 2=7 Hz, 3H) , 1.35 (m, 2=7 Hz, 2H) , 1.55 (m, 2=7 Hz, 2H) , 2.26 (s, 3H) , 2.40 (t, 2=7 Hz, 2H) , 5.85-5.88 (m, IH) , 7.17-7.25 (m,2H), 7.33 (dd, 2=7 and 2 Hz, IH) , 10.20(br s, IH) ; MS (FAB) m/e (rel intenεity) 265 (100) , 249 (3), 221 (10), 201 (2), 187 (8); HMRS: Calc'd for M+H: 265.1108. Found: 265.1126. Step 2: Preparation of 1- (2 -chloro-6 -methylvphenyl) -4- h.. t-vl - -dihvdro-3 - r \ 6- \2- ( lH-tetrazol-5-yl ) phenyl A3 - nyridinvl1methvπ-2H- imidazol-2 -one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 waε converted to 1-(2-chloro-6-methylyphenyl) -4-butyl-l,3-dihydro-3-[ [6- [2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl]-2H- imidazol-2-one as a colorlesε solid: NMR (CDC1 3 ) δ 0.86 (t, 2=7 Hz, 3H) , 1.34 (m, 2=7 Hz, 2H) , 1.49 (m, 2=8 Hz, 2H) , 2.24 (s, 3H) , 2.31 (t, 2=8 Hz, 2H) , 5.05 (d, 2=13 Hz, IH) , 5.15 (d, 2=13 Hz, IH) , 5.98-601 (m, IH) , 7.14 (d, 2=8 Hz, IH) , 7.18-7.25 (m, 2H) , 7.33 (dd, 2=7 and 2 Hz, IH) , 7,41-7.48 (m, 3H) , 7.61 (dd, 2=8 and 2 Hz, IH) , 7.82-7.87 (m, IH) , 8.44 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 500 (55), 472 (15), 457 (5), 237 (15), 209 (100), 194 (36), 180 (96); HMRS: Calc'd for M+H: 500.1966. Found: 500.2028. Example 12 l-(2,6-dimethylphenyl)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5- yl)phenyl]-3-pyridinyl]methyl]-2H-imidazol-2-one Ste 1: Preparation of 1- (2.6-dimethvlphenvl) -4-butvl- 1.3-dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2, 6 -dimethy Iphenyl) -4-butyl-l, 3-dihydro-2H- imidazol-2-one was prepared: NMR (CDC1 3 ) δ 0.91 (t, 2=7 Hz, 3H) , 1.29-1.32 (m, 2H) , 1.49-1.61 (m, 2H) , 2.18 (s, 6H) , 2.41 (t, 2=7 Hz, 2H) , 5.83-5.86 (m, IH) , 7.07-7.21 (m, 3H) , 9.66 (br s, IH) ; MS (FAB) m/e (rel intensity) 245 (100), 215 (4), 118 (9); HMRS: Calc'd for M+H: 245.1654. Found: 245.1668. Step 2: Preparation of 1- (2.6-dimethylphenyl) -4-butyl* 1.3-dihvdro-3-rr6-r2-(lH-tetrazol-5-yl)phenyl1-3- nvridinvnmethvl1-2H- imidazol-2 -one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1- (2,6-dimethyIphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one as a colorleεε εolid: NMR (CDC1 3 ) δ 0.91 (t, 2=8 Hz, 3H) , 1.33-1.47 (m, 2H) , 1.49-1.61 (m, 2H) , 2.09 (ε, 6H) , 2.42 (td, 2=8 and 1 Hz, IH) , 5.09 (s, 2H) , 6.04 (t, 2=1 Hz, IH) , 7.06-7.11 (m, 2H) , 7.14-7.21 (m, IH) , 7.52-7.61 (m, 2H) , 7.62-7.69 (m, 2H) , 7.96-8.07 (m, 2H) , 8.57 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 480 (53), 452 (22), 245 (23), 237 (25), 209 (98), 194 (45), 193 (42), 180 (100); HMRS: Calc'd for M+H: 480.2512. Found: 480.2551. Example 13 l-(2,4,6-trimethylphenyl)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazoI-5- yI)phenyI]-3-pyridinyl]methyI]-2H-imidazoI-2-one Step 1: Preparation of 1- (2 , 4.6-trimethvlphenyl) -4- butvl-1.3-dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2, 4, 6 -trimethy Iphenyl) -4-butyl-l, 3-dihydro-2H- imidazol-2-one was prepared: NMR (CDC1 3 ) δ 0.91 (t, 2=8 Hz, 3H) , 1.28-1.42 (m, 2H) , 1.47-1.60 (m, 2H) , 2.14 (s, 6H) , 2.30 (s, 3H) , 2,40 (t, 2=8 Hz, 2H) , 5.80-5.83 (m, IH) , 6.93 (ε, 2H) , 10.20 (br s, IH) . Step 2: Preparation of 1- (2 , 4 , 6-trimethvlphenyl) -4- b.-t-.vA- ■ -dihvdro- -■ ^ r -r2AlH-t trazol-5-yl) hgnyl A nvr^ri^■nvllmethvll-2H-imidazol-2-one■ Following General Synthetic Schemes XXII and XXIII, the imidazol-2 -one from Step 1 was converted to 1- (2, , 6- rimethy Iphenyl) -4-butyl-l, 3 -dihydro-3 -[ [6- [2- (1H- tetrazol-5-yl) phenyl] -3 -pyridinyl] methyl] -2H-imidazol-2- one as a colorlesε solid: NMR (CDC1 3 ) δ 0.85 (t, 2=8 Hz, 3H) , 1.24-1.38 (m, 2H) , 1.39-1.52 (m, 2H) , 2.05 (s, 6H) , 2.22-2.31 (m, 2H) , 2.26 (s, 3H) , 5.02 (s, 2H) , 5.90 (ε, IH) , 6.82 (ε, 2H) , 7.16 (d, 2=8, IH) , 7.46-7.55 (m, 3H) , 7.60 (dd, 2=8 and 2 Hz, IH) , 7.82-7.89 (m, IH) , 8.47 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intensity) 494 (83), 466 (22), 259 (25), 237 (37), 209 (100), 180 (79); HMRS: Calc'd for M+H: 494.2668. Found: 494.2615. l-(2,6-dimethyl-4-tertbutyIρhenyl)-4-butyI-l,3-dihydro-3-[[6-[2-(lH-tetrazol- yl)phenyI]-3-pyridinyI]methyl]-2H-imidazoI-2-one Step 1: Preparation of 1- (2.6-dimethvl-4- tertbutvlphenvl) -4-butvl-l.3 -dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2, 6 -dimethy 1-4 -tertbuty Iphenyl) -4-butyl-l, 3- dihydro-2H-imidazol-2-one waε prepared: NMR (CDC1 3 ) δ 0.90 (t, 2=8 Hz, 3H) , 1.26-1.42 (m, 2H) , 1.30 (s, 9H) , 1.48-1.60 (m, 2H) , 2.18 (s, 6H) , 2.40 (t, 2=8 Hz, 2H) , 5.83 (ε, IH) , 7.11 (s, 2H) , 10.30 (br s, IH) . Step 2: Preparation of 1- (2.6-dimethyl-4- ter bntvlphenvl) -4-butvl-l.3-dihvdro-3-rr6-r2-(lH- tetrazol-5-vl)phenvl1 -3-Pvridinvllmethvn -2H-imidazol-2- P-e, Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1- (2,6-dimethyl-4-tertbutyIphenyl)-4-butyl-l,3-dihydro- 3-[ [6-[2-(lH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] - 2H-imidazol-2-one as a colorless solid: NMR (CDC1 3 ) δ 0.87 (t, 2=8 Hz, 3H) , 1.25-1.41 (m, 2H) , 1.32 (s, 9H) , 1.43-1.55 (m, 2H) , 2.15 (ε, 6H) , 2.32 (t, 2=8, 2H) , 5.09 (s, 2H) , 5.96 (s, IH) , 7.13 (ε, 2H) , 7.19 (d, 2=8 Hz, IH) 7.45-7.54 (m, 3H) , 7.63 (dd, 2=8 and 2 Hz, IH) , 7.90-7.97 (m, IH) , 8.49 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intenεity) 536 (36), 508 (18), 301 (19), 243 (26), 208 (100), 180 (90); HMRS: Calc'd for M+H: 536.3138. Found: 536.3098. Example 15 l-(2,6-diethylphenyI)-4-butyI-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5- yI)phenyl]-3-pyridinyI]methyI]-2H-imιdazol-2-one Step 1: Preparation of 1- (2.6-diethylphenyl) -4-butyl- 1. -dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2, 6-diethylphenyl) -4-butyl-l, 3-dihydro-2H- imidazol-2-one was prepared: NMR (CDC1 3 ) δ 0.89 (t, 2=7 Hz, 3H) , 1.17 (t, 2=7 Hz, 6H) , 1.33 (m, 2=7 Hz, 2H) , 1.53 (m, 2=8 Hz, 2H) , 2.40 (t, 2=7 Hz, 2H) , 2.50 (q, 2=8 Hz, 2H) , 2.52 (q, 2=8 Hz, 2H) , 5.82-5.84 (m, IH) , 7.16 (d, 2=8 Hz, 2H) , 7.26-7.33 (m, IH) , 10.71 (br s, IH) ; MS (FAB) m/e (rel intensity) 273 (100), 255 (15); HMRS: Calc'd for M+H: 273.1967 Found: 273.1980. Step 2: Preparation of 1- (2.6-diethvlphenvl) -4-butyl- 1. -dihvdro-3- r . - \ 2 - (lH-tetrazol-5-yl)phenyll -3- nvridinvl1methvl1 -2H-imidazol-2-one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to l-(2, 6-diethylphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one as a colorless solid: NMR (CDC1 3 ) δ 0.86 (t, 2=7 Hz, 3H) , 1.12 (t, 2=8 Hz, 6H) , 1.33 (m, 2=8 Hz, 2H) , 1.48 (m, 2=8 Hz, 2H) , 2.33 (t, 2=7 Hz, 2H) , 2.37-2.54 (m, 4H) , 5.08 (s, 2H) , 5.95 (ε, IH) , 7.12 (d, 2=8 Hz, 2H) , 7.24-7.31 (m, IH) , 7.43-7.49 (m, 3H) , 7.63 (dd, 2=6 and 2 Hz, IH) , 7.80-7.87 (m, IH) , 8.44-8.48 (m, IH) ; MS (FAB) m/e (rel intenεity) 508 (53), 480 (27), 465 (7), 237 (17), 209 (100), 194 (26), 180 (60); HRMS: Calc'd for M+H: 508.2825. Found: 508.2833. Example 16 l-(2,6-diisopropylphenyl)-4-butyl-l,3-dihydro-3-[[6-[2-(lH-tetrazol-5- yI)phenyI]-3-pyridinyl]methyl]-2H-imidazoI-2-one Step 1: Preparation of 1-(2.6-diisopropylphenyl) -4- butyl-1.3-dihvdro-2H-imidazol-2-one. Following General Synthetic Schemes III and IV, 1- (2,6-diisoprop Iphenyl) -4-butyl-l, 3-dihydro-2H- imidazol-2-one waε prepared: NMR (CDC1 3 ) δ 0.92 (t, 2=8 Hz, 3H) , 1.16 (d, 2=8 Hz, 6H) , 1.23 (d, 2=8 Hz, 6H) , 1.29-1.44 (m, 2H) , 1.50-1.61 (m, 2H) , 2.41 (t, 2=8 Hz, 2H) , 2.75-2.91 (m, 2H) , 5.85 (t, 2=1 Hz, IH) , 7.22 (d, 2=8 Hz, 2H) , 7.36 (t, 2=8 Hz, IH) . Step 2: Preparation of 1- (2.6-diisopropvlphenyl) -4- hπtvA1.3-dihvdro-3-rr6-r2-(lH-tetrazol-5-yl)phenvπ-3- pvτ-idinvl1methvπ-2H-imidazol-2-one. Following General Synthetic Schemes XXII and XXIII, the imidazol-2-one from Step 1 was converted to 1- (2,6-diisopropyIphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2- dH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]-2H- imidazol-2-one as a colorless solid: NMR (CDC1 3 ) δ 0.87 (t, 2=7 Hz, 3H) , 1.19 (d, 2=7 Hz, 6H) , 1.21 (t, 2=7 Hz, 3H) , 1.28-1.42 (m, 2H) , 1.44-1.56 (m, 2H) , 2.35 (t, 2=8 Hz, 2H) , 2.69-2.84 (m, 2H) , 5.08 (s, 2H) , 5.96 (ε, IH) , 7.20-7.29 (m, 3H) , 7.34-7.53 (m, 4H) , 7.69 (dd, 2=8 and 2 Hz, IH) , 7.92-7.97 (m, IH) , 8.49 (d, 2=2 Hz, IH) ; MS (FAB) m/e (rel intenεity) 536 (28), 237 (22), 209 (23); HRMS: Calc'd for M+H: 536.3138 Found: 536.3102. BIOLOGICAL EVALUATION Assay A: Angiotensin II Binding Activity Compounds of the invention were tested for ability to bind to the smooth muscle angiotenεin II receptor uεing a rat uterine membrane preparation. Angiotenεin II (All) was purchased from Peninsula Labs. -**-25-j-_ an gi 0 tensin n (specific activity of 2200 Ci/mmol) was purchased from Du Pont-New England Nuclear. Other chemicals were obtained from Sigma Chemical Co. This assay was carried out according to the method of Douglas et al fEndocrinology. 106. 120-124 (1980)]. Rat uterine membranes were prepared from freεh tiεsue. All procedures were carried out at 4°C. Uteri were stripped of fat and homogenized in phoεphate-buffered εaline at pH 7.4 containing 5 mM EDTA. The ho ogenate waε centrifuged at 1500 x g for 20 min. , and the εupernatant waε recentrifuged at 100,000 x g for 60 min. The pellet was resuεpended in buffer consisting of 2 mM EDTA and 50 mM Tris-HCl (pH 7.5) to a final protein concentration of 4 mg/ml. Aεεay tubeε were charged with 0.25 ml of a solution containing 5 mM MgCl2, 2 mM EDTA, 0.5% bovine serum albumin, 50 mM Tris-HCl, pH 7.5 and 12 5 I _ AII (approximately 10^ cpm) in the absence or in the presence of unlabelled ligand. The reaction was initiated by the addition of membrane protein and the mixture was incubated at 25°C for 60 min. The incubation was terminated with ice-cold 50 mM Tris-HCl (pH 7.5) and the mixture waε filtered to εeparate membrane-bound labelled peptide from the free ligand. The incubation tube and filter were waεhed with ice-cold buffer. Filterε were aεεayed for radioactivity in a Micromedic gamma counter. Nonεpecific binding was defined as binding in the presence of 10 μM of unlabelled All. Specific binding was calculated as total binding minus nonspecific binding. The receptor binding affinity of an All antagonist compound was indicated by the concentration (IC50) of the tested All antagonist which gives 50% displacement of the total specifically bound 1 25 I-AII from the high affinity All receptor. Binding data were analyzed by a nonlinear least-squares curve fitting program. Results are reported in Table I. Assay R; In Vitro Vascular Smooth Muscle-Response for The compounds of the invention were tested for antagonist activity in rabbit aortic rings. Male New Zealand white rabbits (2-2.5 kg) were sacrificed using an overdose of pentobarbital and exsanguinated via the carotid arteries. The thoracic aorta was removed, cleaned of adherent fat and connective tissue and then cut into 3-mm ring segments. The endothelium was removed from the rings by gently sliding a rolled-up piece of filter paper into the vessel lumen. The rings were then mounted in a water-jacketed tisεue bath, maintained at 37°C, between moveable and fixed endε of a εtainleεε steel wire with the moveable end attached to an FT03 Grass transducer coupled to a Model 7D Grasε Polygraph for recording isometric force responses. The bath was filled with 20 ml of oxygenated (95% oxygen/5% carbon dioxide) Krebs solution of the following composition (mM) : 130 NaCl, 15 NaHCθ3, 15 KCl, 1.2 NaH2P0 , 1.2 MgS04, 2.5 CaCl2, and 11.4 glucose. The preparations were equilibrated for one hour before approximately one gram of passive tension was placed on the rings. Angiotensin II concentration-responεe curveε were then recorded (3 X 10 "10 to 1 X 10 ~5 M) . Each concentration of All waε allowed to elicit its maximal contraction, and then All was washed out repeatedly for 30 minutes before rechallenging with a higher concentration of All. Aorta rings were expoεed to the teεt antagoniεt at 10 ~ 5 M for 5 minuteε before challenging with All. Adjacent εegmentε of the same aorta ring were used for all concentration-response curves in the preεence or abεence of the teεt antagoniεt. The effectiveness of the test compound was expressed in terms of pA2 values and were calculated according to H.O. Schild fBr. J. Pharmacol. Chemother. , 2,189-206 (1947)]. The pA 2 value is the concentration of the antagonist which increases the EC50 value for All by a factor of two. Each test antagoniεt waε evaluated in aorta ringε from two rabbitε. Reεults are reported in Table I. Assay C: In Vivo Intragastric Pressor Assay Response for l Antagonists Male Sprague-Dawley rats weighing 225-300 grams were aneεthetized with methohexital (30 mg/kg, i.p.) and catheters were implanted into the femoral artery and vein. The catheters were tunneled εubcutaneouεly to exit dorεally, posterior to the head and between the scapulae. The catheters were filled with heparin (1000 units/ml of εaline) . The ratε were returned to their cage and allowed regular rat chow and water ad libitum. After full recovery from εurgery (3-4 days) , rats were placed in Lucite holderε and the arterial line waε connected to a preεεure tranεducer. Arterial pressure was recorded on a Gould polygraph (mmHg) . Angiotensin II waε administered as a 30 ng/kg boluε via the venouε catheter delivered in a 50 μl volume with a 0.2 ml saline flush. The presεor reεponse in mm Hg was measured by the difference from pre- injection arterial pressure to the maximum pressure achieved. The All injection was repeated every 10 minutes until three consecutive injections yielded responεeε within 4 mmHg of each other. Theεe three reεponεeε were then averaged and repreεented the control reεponεe to All. The test compound waε εuspended in 0.5% methylcelluloεe in water and was administered by gavage. The volume administered was 2 ml/kg body weight. The εtandard dose was 3 mg/kg. Angiotensin II bolus injections were given at 30, 45, 60, 75, 120, 150, and 180 minutes after gavage. The presεor response to All was measured at each time point. The rats were then returned to their cage for future testing. A minimum of 3 days waε allowed between tests. Percent inhibition was calculated for each time point following gavage by the following formula: [ (Control Response - Response at time point) /Control Response] X 100. Resultε are εhown in Table I. TAEI.E X In Vitro and In Vivo Angiotensin II Activity of Compounds of the Invention administered intragastrically at 3 mg/kg) . *NT= Not Tested Also embraced within this invention is a class of pharmaceutical compositions comprising one or more compounds of Formula I in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art. The compounds and composition may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspenεion or liquid. The pharma¬ ceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. These may with advantage contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose of from about 0.1 to 3000 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight, may be appropriate. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose is from about 0.1 to 100 mg/kg body weight injected per day in multiple doses depending on the disease being treated. A preferred daily dose would be from about 1 to 30 mg/kg body weight. Compounds indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 100 mg per kilogram of body weight per day. A more preferred dosage will be a range from about 1 mg to about 100 mg per kilogram of body weight. Most preferred is a dosage in a range from about 1 to about 50 mg per kilogram of body weight per day. A suitable dose can be administered, in multiple sub-doses per day. These sub- doses may be administered in unit dosage forms. Typically, a dose or sub-dose may contain from about 1 mg to about 100 mg of active compound per unit dosage form. A more preferred dosage will contain from about 2 mg to about 50 mg of active compound per unit dosage form. Most preferred is a dosage form containing from about 3 mg to about 25 mg of active compound per unit dose. The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of administration, and the particular compound employed, and thus may vary widely. For therapeutic purposes, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for con¬ venient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxy- propyImethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non- aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, ■ and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

Claims: 223 What Is Claimed Is: A compound of Formula I wherein A is selected from wherein m is a number selected from one to four, inclusive; wherein each of R^, R 2 and R3 is independently selected from hydrido, alkyl, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and haloalkylcarbonyl; wherein R^ is selected from hydrido, alkyl, halo, haloalkyl, formyl, carboxyl and alkoxyalkyl; wherein R^ is selected from alkylphenyl, phenylalkyl, cycloalkyl and cycloalkylalkyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 2. Compound of Claim 1 of Formula II wherein each of R 1 , R 2 and R3 iε independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R^ is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein Ε>β is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 3. Compound of Claim 2 wherein each of R 1 is selected from methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R^ is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R> is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. -1 4. Compound of Claim 2 wherein each of R and R is independently selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R- 1 is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R*= is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Compound of Claim 1 of Formula III wherein each of R 1 , R 2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R 4 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R 5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 6. Compound of Claim 5 wherein each of Έ - is selected from methyl, ethyl, n-propyl, isopropyl, tert- butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R 4 is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 7. Compound of Claim 5 wherein each of R 1 and R is independently selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R 3 and R is hydrido; wherein R 5 is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, n-pentyl, isopentyl and neopentyl; wherein R is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 8. Compound of Claim 5 which is l-phenyl-4- butyl-1,3-dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl] ethyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 9. Compound of Claim 5 which is l-(2- chlorophenyl) -4-butyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol- 5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 10. Compound of Claim 5 which is l-(2- methylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol- 5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 11. Compound of Claim 5 which is l-(2- methoxyphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 12. Compound of Claim 5 which is l-(2- ethylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2-(lH-tetrazol- 5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 13. Compound of Claim 5 which is l-(2- isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 14. Compound of Claim 5 which is l-(2- tertbutylphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 15. Compound of Claim 5 which is l-(2,6- difluorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 16. Compound of Claim 5 which is l-(2,6- dichlorophenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 17. Compound of Claim 5 which is l-(2,6- dimethoxyphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 18. Compound of Claim 5 which is l-(2-chloro- 6-methylyphenyl) -4-butyl-l,3-dihydro-3- [ [6-[2- (1H- tεtrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 19. Compound of Claim 5 which is l-(2,6- dimethylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 20... Compound of Claim 5 which is l-(2,4,6- rimethyIphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl] ethyl]-2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 21. Compound of Claim 5 which is l- (2 , 6- dimethyl -4 -tertbutylphenyl ) -4-butyl-l , 3 -dihydro-3 - [ [ 6- [2- ( lH-tetrazol-5-yl ) phenyl ] -3 -pyridinyl]methyl ] -2H- imidazol-2 -one or a pharmaceutically-acceptable salt thereof . 22. Compound of Claim 5 which is l-(2,6- diethyIphenyl) -4-butyl-l,3-dihydro-3-[ [6-[2-(lH- tetrazol-5-yl)phenyl]-3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 23. Compound of Claim 5 which is l-(2,6- diisopropyIphenyl)-4-butyl-l,3-dihydro-3-[ [6-[2-(1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2■ one or a pharmaceutically-acceptable salt thereof. 24. Compound of Claim 4 of Formula IV wherein each of R^-, R and R 3 iε independently εelected from hydrido, methyl, ethyl, n-propyl, iεopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, for yl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R 4 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R 5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 25. Compound of Claim 24 wherein each of R 1 is selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R 4 is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 26. Compound of Claim 24 wherein each of Rι and R is independently selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, fonπyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 27. Compound of Claim 1 of Formula V wherein each of R^, R and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R^ is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R^ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R^ is an acidic group selected from COOH and 0 or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 28. Compound of Claim 27 wherein each of R 1 is selected from methyl, ethyl, n-propyl, isopropyl, 5 tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R^ is hydrido; wherein R 5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- C butyl, n-pentyl, isopentyl and neopentyl; wherein R 6 is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 29. Compound of Claim 27 wherein each of Rl and R2 i•s i■ndependently selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R 5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 30. Compound of Claim 1 of Formula VI o wherein each of Rl, R2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R 4 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R6 is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 31. Ccnpound of Claim 30 wherein each of R1 is selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R 3 and R^ is hydrido; wherein R^ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and I or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. ι 32. Compound of Claim 30 wherein each of R and R is independently selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 33. Compound of Claim 1 of Formula VII wherein each of Rl, R2 and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R^ is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R^ is an acidic group selected from COOH and H or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 34. Compound of Claim 33 wherein each of R 1 is selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R 3 and R 4 is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. *-] 35. Compound of Claim 33 wherein each of R 2 and R is independently selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 36. A pharmaceutical composition comprising a therapeutically-effective amount of an angiotensin II antagonist compound and a pharmaceutically-acceptable carrier or diluent, said antagonist compound selected from a family of compounds of Formula III: wherein each of Rl, R2 and R 3 is independently εelected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R 4 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R-5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R6 is an acidic group selected from COOH and H I or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 37. The compositon of Claim 36 wherein each of Rl is selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R 3 and R 4 is hydrido; wherein R5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R6 is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 38. The compositon of Claim 36 wherein each of R 1 and R2 is independently selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R 6 is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 39. The composition of Claim 36 wherein said antagonist is 1-phenyl-4-butyl-1,3-dihydro-3- [ [6-[2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 40. The composition of Claim 36 wherein said antagonist is 1-(2-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or. a pharmaceutically-acceptable salt thereof. 41. The composition of Claim 36 wherein said antagonist is 1- (2-methylphenyl) -4-butyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof. 42. The compoεition of Claim 36 wherein said antagonist is 1- (2-methoxyphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof. 43. The composition of Claim 36 wherein said antagonist is 1- (2-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof. 44. The composition of Claim 36 wherein said antagonist is 1- (2-isopropylphenyl) -4-butyl-l, 3-dihydro- 3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] - 2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 45. The composition of Claim 36 wherein said antagonist is 1- (2-tertbutylphenyl) -4-butyl-l, 3-dihydro- 3-[ [6-[2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] - 2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 46. The composition of Claim 36 wherein said antagonist is 1- (2, 6-difluorophenyl) -4-butyl-l, 3- dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 47. The composition of Claim 36 wherein said antagonist is 1- (2, 6-dichlorophenyl) -4-butyl-l, 3- dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 48. The compoεition of Claim 36 wherein said antagonist is 1- (2, 6-dimethoxyphenyl) -4-butyl-l, 3- dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 49. The composition of Claim 36 wherein said antagonist is 1- (2-chloro-6-methylyphenyl) -4-butyl-l, 3- dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 50. The composition of Claim 36 wherein said antagonist is 1- (2, 6-dimethyIphenyl) -4-butyl-l,3- dihydro-3-[ [6-[2-(lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 51. The composition of Claim 36 wherein said antagonist is 1-(2,4, 6-trimethylphenyl) -4-butyl-l,3- dihydro-3-[ [6-[2-(lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 52. The composition of Claim 36 wherein said antagonist is 1-(2, 6-dimethyl-4-tertbutyIphenyl) -4- butyl-1,3-dihydro-3- [ [6-[2-(lH-tetrazol-5-yl)phenyl] -3- pyridinyl] ethyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 53. The composition of Claim 36 wherein said antagonist is 1- (2, 6-diethylphenyl) -4-butyl-l,3-dihydro- 3-t [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] - 2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 54. The composition of Claim 36 wherein said antagonist is 1- (2, 6-diisopropyIphenyl) -4-butyl-l,3- dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 55. A therapeutic method for treating a circulatory disorder or a circulatory-related disorder, said method comprising administering to a subject susceptible to or afflicted with such disorder a therapeutically-effective amount of an active compound of Formula III: wherein each of R 1 , R and R 3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, tert¬ butyl, methoxy, ethoxy, propoxy, isopropoxy, tert- butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N-methylamino, N,N-dimethylamino, N- ethylamino, N,N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; wherein R 4 is selected from hydrido, methyl, fluoro, chloro, onofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R^ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyImethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 56. The method of Claim 55 wherein each of R 1 is selected from methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R , R and R 4 is hydrido; wherein R-5 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 57. The method of Claim 55 wherein each of R and R is independently selected from methyl, ethyl, n- propyl, isopropyl, tert-butyl, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; wherein each of R and R is hydrido; wherein R is selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert¬ butyl, n-pentyl, isopentyl and neopentyl; wherein R^ is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. 58. The method of Claim 55 wherein said active compound is l-phenyl-4-butyl-l,3-dihydro-3- [ [6- [2- (1H- tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H-imidazol-2- one or a pharmaceutically-acceptable salt thereof. 59. The method of Claim 55 wherein said active compound is 1- (2-chlorophenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof. 60. The method of Claim 55 wherein said active compound is 1- (2-methylphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof . 61. The method of Claim 55 wherein said active compound is 1- (2-methoxyphenyl) -4-butyl-l, 3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof . 62. The method of Claim 55 wherein said active compound iε 1- (2-ethyIphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof . 63. The method of Claim 55 wherein said active compound is 1- (2-isopropylphenyl) -4-butyl-l,3-dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof. 64. The method of Claim 55 wherein said active compound is 1- (2-tertbutylphenyl) -4-butyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof. 65. The method of Claim 55 wherein said active compound is 1- (2, 6-difluorophenyl) -4-butyl-l,3-dihydro- 3-[ [6-[2-(lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] - 2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 66. The method of Claim 55 wherein said active compound is 1- (2, 6-dichlorophenyl) -4-butyl-l,3-dihydro- 3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] - 2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 67. The method of Claim 55 wherein said active compound is 1- (2, 6-dimethoxyphenyl) -4-butyl-l,3-dihydro- 3- [ [6- [2- (IH-tetrazol-5-yl)phenyl] -3-pyridinyl] ethyl] - 2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 68. The method of Claim 55 wherein said active compound is 1- (2-chloro-6-methylyphenyl) -4-butyl-l,3- dihydro-3- [ [6- [2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl] ethyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 69. The method of Claim 55 wherein said active compound is 1-(2, 6-dimethylphenyl)-4-butyl-l,3-dihydro- 3-[ [6-[2- (IH-tetrazol-5-yl)phenyl]-3-pyridinyl]methyl]- 2H-imidazol-2-one or a pharmaceutically-acceptable εalt thereof. 70. The method of Claim 55 wherein said active compound is 1- (2,4, 6-trimethylphenyl) -4-butyl-l,3- dihydro-3-[ [6-[2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 71. The method of Claim 55 wherein said active compound is 1- (2, 6-dimethyl-4-tertbutyIphenyl) -4-butyl- 1,3-dihydro-3-[ [6-[2-(lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 72. The method of Claim 55 wherein said active compound is 1- (2,6-diethylphenyl)-4-butyl-l,3-dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl] -3-pyridinyl]methyl] -2H- imidazol-2-one or a pharmaceutically-acceptable salt thereof. 73. The method of Claim 55 wherein said active compound is 1- (2, 6-diisopropyIphenyl) -4-butyl-l,3- dihydro-3- [ [6-[2- (lH-tetrazol-5-yl)phenyl] -3- pyridinyl]methyl] -2H-imidazol-2-one or a pharmaceutically-acceptable salt thereof. 74. The method of Claim 55 wherein said circulatory disorder is a cardiovascular disorder. 75. The method of Claim 74 wherein said cardiovascular disorder is hypertension. 76. The method of Claim 74 wherein said cardiovascular disorder is congestive heart failure. 77. The method of Claim 55 wherein said circulatory-related disorder is glaucoma.

Inventors: MANNING ROBERT E, REITZ DAVID B, MANNING, ROBERT, E., REITZ, DAVID, B.
Applicants: MANNING ROBERT E, REITZ DAVID B, SEARLE & CO, G.D. SEARLE & CO.
Application year: 1993
Main classification: C07D401
IPC codes: A61K31, A61P9, A61P27, C07D401